Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 11-14 December 2023

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

11 December 2023, 09:00 – 19:30, virtual meeting/room 2C
12 December 2023, 08:30 – 19:30, virtual meeting/room 2C
13 December 2023, 08:30 – 19:30, virtual meeting/room 2C
14 December 2023, 08:30 – 15:00, virtual meeting/room 2C

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

## 1. Introduction
- 1.1. Welcome and declarations of interest of members, alternates and experts .......................... 8
- 1.2. Adoption of agenda ........................................................................................................ 8
- 1.3. Adoption of the minutes ............................................................................................... 8

## 2. Oral Explanations
- 2.1. Pre-authorisation procedure oral explanations ........................................................... 8
  - 2.1.1. sparsentan - Orphan - EMEA/H/C/005783 .......................................................... 8
  - 2.1.2. leriglitazone - Orphan - EMEA/H/C/005757 ..................................................... 8
  - 2.1.3. pegcetacoplan - EMEA/H/C/005954 ............................................................... 9
- 2.2. Re-examination procedure oral explanations ............................................................... 9
  - 2.2.1. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan .............. 9
- 2.3. Post-authorisation procedure oral explanations .......................................................... 9
- 2.4. Referral procedure oral explanations .......................................................................... 9
  - 2.4.1. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529 .................................... 9

## 3. Initial applications
- 3.1. Initial applications; Opinions ....................................................................................... 10
  - 3.1.1. arpraziquantel - Article 58 - EMEA/H/W/004252 .............................................. 10
  - 3.1.2. exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763 ...... 10
  - 3.1.3. dabigatran etexilate - EMEA/H/C/005922 ....................................................... 10
  - 3.1.4. eribulin - EMEA/H/C/006134 ........................................................................... 10
  - 3.1.5. ibuprofen - EMEA/H/C/006129 ....................................................................... 10
  - 3.1.6. Pomalidomide - EMEA/H/C/006195 ............................................................... 11
  - 3.1.7. omaveloxolone - Orphan - EMEA/H/C/006084 ............................................. 11
  - 3.1.8. etrasimod - EMEA/H/C/006007 ....................................................................... 11
- 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) .................................................. 11
  - 3.2.1. concizumab - EMEA/H/C/005938 ................................................................. 11
  - 3.2.2. apremilast - EMEA/H/C/006208 ............................................................... 12
  - 3.2.3. aumolertinib - EMEA/H/C/006069 ............................................................ 12
  - 3.2.4. buprenorphine - EMEA/H/C/006188 .......................................................... 12
  - 3.2.5. sugemalimab - EMEA/H/C/006088 ............................................................ 12
  - 3.2.6. serplulimab - Orphan - EMEA/H/C/006170 ................................................. 12
  - 3.2.7. aprocitentan - EMEA/H/C/006080 ............................................................ 12
  - 3.2.8. omecamtiv mecarbil - EMEA/H/C/006112 ................................................... 13
  - 3.2.9. nintedanib - EMEA/H/C/006179 ............................................................... 13
  - 3.2.10. ustekinumab - EMEA/H/C/006183 ........................................................... 13
3.2.11. flortaucipir (18F) - EMEA/H/C/006064 ................................................................. 13
3.2.12. retifanlimab - Orphan - EMEA/H/C/006194 ...................................................... 13

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) ........................................................................ 14
3.3.1. delgocitinib - EMEA/H/C/006109 ....................................................................... 14
3.3.2. givinostat - Orphan - EMEA/H/C/006079 ......................................................... 14
3.3.3. aztreonam / avibactam - EMEA/H/C/006113 ...................................................... 14
3.3.4. enzalutamide - EMEA/H/C/006299 .................................................................... 14
3.3.5. insulin glargine - EMEA/H/C/006136 ................................................................. 14
3.3.6. vilobelimab - EMEA/H/C/006123 ..................................................................... 14
3.3.7. trastuzumab - EMEA/H/C/006252 .................................................................... 15
3.3.8. avacincaptad pegol - EMEA/H/C/006153 .......................................................... 15
3.3.9. donanemab - EMEA/H/C/006024 .................................................................... 15
3.3.10. temozolomide - Orphan - EMEA/H/C/006169 ................................................ 15
3.3.11. zapomeran – OPEN – EMEA/H/C/006207 ...................................................... 15
3.3.12. odronextamab - Orphan - EMEA/H/C/006215 ............................................... 15
3.3.13. lutetium (177Lu) chloride - EMEA/H/C/005882 ................................................. 15
3.3.14. ciclosporin - EMEA/H/C/006250 ...................................................................... 16

3.4. Update on on-going initial applications for Centralised procedure .................... 16
3.4.1. catumaxomab - EMEA/H/C/005697 ................................................................. 16
3.4.2. methylphenidate hydrochloride - PUMA - EMEA/H/C/005975 ......................... 16
3.4.3. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/006053 .......... 16
3.4.4. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165 .......... 16
3.4.5. polihexanide - Orphan - EMEA/H/C/005858 ..................................................... 17

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 ..................................................................................................... 17

3.6. Initial applications in the decision-making phase ............................................. 17

3.7. Withdrawals of initial marketing authorisation application ............................. 17

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 ................................................................. 17
4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion ................................................................. 17
4.1.1. Entyvio - vedolizumab - EMEA/H/C/002782/X/0075 ........................................ 17
4.1.2. Lumykras - sotorasib - EMEA/H/C/005522/X/0009 ............................................ 18
4.1.3. Viagra - sildenafil - EMEA/H/C/000202/X/0115 ............................................... 18

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues ..................... 18
4.2.1. Teriflunomide Accord - teriflunomide - EMEA/H/C/005960/X/0002 ................. 18
4.2.2. Kalydeco - ivacaftor - EMEA/H/C/002494/X/0115/G ........................................ 18
4.2.3. Opdivo - nivolumab - EMEA/H/C/003985/X/0132 ........................................... 19
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question ................................................................. 19
4.3.1. Edurant - rilpivirine - EMEA/H/C/002264/X/0042/G ........................................ 19
4.3.2. Eliquis - apixaban - EMEA/H/C/002148/X/0089/G ..................................... 20
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 ................................................................. 20
4.4.1. Reagila - Cariprazine - EMEA/H/C/002770/X/0033 ................................. 20
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 ............................ 20

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information ........................................................................................................... 21
5.1.1. Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0012 ................................................................. 21
5.1.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - ATMP - EMEA/H/C/005095/II/0021 ................................................................. 21
5.1.3. Cibinco - abroctinib - EMEA/H/C/005452/II/0010 ........................................ 22
5.1.4. Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320/II/0016 .......... 22
5.1.5. HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0087 ......... 22
5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0134 ............................. 23
5.1.7. Kisqali - ribociclib - EMEA/H/C/004213/II/0045 ......................................... 23
5.1.8. LIVMARLI - maralixibat - Orphan - EMEA/H/C/005857/II/0003/G .............. 23
5.1.9. Metalyse - Tenecteplase - EMEA/H/C/000306/II/0070/G ......................... 24
5.1.10. Palforzia - defatted powder of arachis hypogaea L., semen (peanuts) - EMEA/H/C/004917/II/0014/G ................................................................. 24
5.1.11. SCENESSE - afamelanotide - Orphan - EMEA/H/C/002548/II/0044 .......... 25
5.1.12. TAGRISSO - osimertinib - EMEA/H/C/004124/II/0053 ............................. 25
5.1.13. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0081 ............................ 25
5.1.14. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0082 ............................ 26
5.1.15. Valdoxan - agomelatine - EMEA/H/C/000915/II/0051 ............................ 26
5.1.16. VeraSeal - human fibrinogen / human thrombin - EMEA/H/C/004446/II/0027 ................................. 26
5.1.17. Xtandi - enzalutamide - EMEA/H/C/002639/II/0063 ............................... 27
5.1.18. Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0037 ........................... 27

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ................................................ 28

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ................................. 28
6. Medical devices

6.1. Ancillary medicinal substances - initial consultation ............................................. 28
6.3. Companion diagnostics - initial consultation ..................................................... 29
6.3.1. In vitro diagnostic medical device - EMEA/H/D/006372 ...................................... 29
6.3.2. In vitro diagnostic medical device - EMEA/H/D/006373 ...................................... 29
6.3.3. in vitro diagnostic medical device - EMEA/H/D/006341 ..................................... 29
6.4. Companion diagnostics – follow-up consultation ................................................ 29

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 29

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 29

8. Pre-submission issues

8.1. Pre-submission issue ............................................................................................ 30
8.1.1. obecabtagene autoleucel - H0005907 ................................................................. 30
8.1.2. Sipavibart - H0006291 ...................................................................................... 30
8.1.3. lazertinib - H0006074 ....................................................................................... 30
8.1.4. Dorocubicel/Allogeneic umbilical cord-derived CD34- cells, non-expanded – PRIME - H0005772 ................................................................. 30
8.2. Priority Medicines (PRIME) ................................................................................ 30

9. Post-authorisation issues

9.1. Post-authorisation issues ....................................................................................... 31
9.1.1. Bimervax - sars-cov-2 virus, variants b.1.351-b.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058/II/0004 .................................................. 31
9.1.2. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan ............ 31
9.1.3. LUMYKRAS - Sotorasib - EMEA/H/C/005522/II/0010/G ................................. 31
9.1.4. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan .......................... 32
9.1.5. Tremelimumab AstraZeneca - tremelimumab - EMEA/H/C/004650/II/0002 ...... 32
9.1.6. Clopidogrel BGR (SRD) – clopidogrel – EMEA/H/C/001138 .......................... 32
9.1.7. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0095 . 32
9.1.8. Holoclar - Ex vivo expanded autologous human corneal epithelial cells containing stem cells - EMEA/H/C/002450/R/0058, Orphan, ATMP ........................................ 33

10. Referral procedures

10.1.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065 .............................................................. 33
10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 . 34
10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 .......... 34
10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) – under Article 29(4) of Directive 2001/83/EC ............................................................................................................... 34
10.4.1. Ibuprofen NVT – ibuprofen - EMEA/H/A-29(4)/1533 .................................................. 34
10.5.1. Havrix – Hepatitis A virus (inactivated, adsorbed) - EMEA/H/A-30/1527 ................. 34
10.6.1. Azithromycin containing medicinal products for systemic use – various – EMEA/H/A-31/153234
10.6.2. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529 ........................................... 35
10.9. Disagreement between Member States on Type II variation – Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 ............................................................................................................ 35
10.11. Referral under Article 13 Disagreement between Member States on Type II variation – Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 ........................................................................ 36

11. Pharmacovigilance issue 36
11.1. Early Notification System ..................................................................................... 36

12. Inspections 36
12.1. GMP inspections ................................................................................................... 36
12.2. GCP inspections .................................................................................................... 36
12.3. Pharmacovigilance inspections ............................................................................. 36
12.4. GLP inspections .................................................................................................... 36

13. Innovation Task Force 37
13.1. Minutes of Innovation Task Force ......................................................................... 37
13.2. Innovation Task Force briefing meetings .............................................................. 37
13.4. Nanomedicines activities ...................................................................................... 37

14. Organisational, regulatory and methodological matters 37
14.1. Mandate and organisation of the CHMP ............................................................... 37
14.1.1. Vote by proxy ....................................................................................................... 37
14.2. Coordination with EMA Scientific Committees ................................................... 37
14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) ................................. 37
14.2.2. Paediatric Committee (PDCO) ............................................................................ 37
14.2.3. Joint CHMP-CAT membership ........................................................................ 37
14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ...... 38
14.3.1. Biologics Working Party (BWP) ................................................................. 38
14.3.2. Call for nomination of new member (BWP) ................................................ 38
14.3.3. Name Review Group (NRG) ..................................................................... 38
14.3.4. Scientific Advice Working Party (SAWP) .................................................. 38
14.3.5. Call for interest for nomination of a replacement SAWP member .......... 39
14.3.6. Nominations of PRAC and QRD representatives ..................................... 39
14.4. Cooperation within the EU regulatory network ............................................ 39
14.5. Cooperation with International Regulators ............................................... 39
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee ................................................................. 39
14.7. CHMP work plan ....................................................................................... 39
14.7.1. CHMP Workplan 2024 ............................................................................ 39
14.8. Planning and reporting ............................................................................. 39
14.8.1. Update of the Business Pipeline report for the human scientific committees ......................... 39
14.9. Others ...................................................................................................... 40
14.9.1. CHMP Learnings ................................................................................... 40

15. Any other business ....................................................................................... 40
15.1. AOB topic ................................................................................................. 40

Explanatory notes ......................................................................................... 41
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 11-14 December 2023. See December 2023 CHMP minutes (to be published post January 2024 CHMP meeting).

1.2. **Adoption of agenda**

CHMP agenda for 11-14 December 2023.

1.3. **Adoption of the minutes**

CHMP minutes for 06-09 November 2023.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 04 December 2023.

2. **Oral Explanations**

2.1. **Pre-authorisation procedure oral explanations**

2.1.1. **sparsentan - Orphan - EMEA/H/C/005783**

Vifor France; for the treatment of primary immunoglobulin A nephropathy (IgAN).

Scope: Possible oral explanation

**Action**: Possible oral explanation to be held on 12 December 2023 at 16:00


2.1.2. **leriglitazone - Orphan - EMEA/H/C/005757**

Minoryx Therapeutics S.L.; the treatment of cerebral progression and myelopathy in male patients with adrenoleukodystrophy (ALD).

Scope: Oral explanation

**Action**: Oral explanation to be held on 12 December 2023 at 11:00

2.1.3. pegcetacoplan - EMEA/H/C/005954

Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Scope: Oral explanation

Action: Oral explanation to be held on 13 December 2023 at 14:00


2.2. Re-examination procedure oral explanations

2.2.1. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan

GlaxoSmithKline (Ireland) Limited

Scope: Oral explanation

Action: Oral explanation to be held on 12 December 2023 at 14:00


See 9.1

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

2.4.1. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529

MAH Various

Referral Rapporteur: Maria Concepcion Prieto Yerro, Referral Co-Rapporteur: Janet Koenig

Scope: Oral explanation

Action: Oral explanation to be held on 12 December 2023 at 09:00

Article 31 procedure triggered by the Agency of Medicines and Medical Devices (AEMPS) in Spain, concerning the contract research organisation (CRO) Synapse Labs Pvt. Ltd., located in Kharadi, Pune, India.

See 10.6
3. Initial applications

3.1. Initial applications; Opinions

3.1.1. arpraziquantel - Article 58 - EMEA/H/W/004252

treatment of schistosomiasis in children
Scope: Opinion
Action: For adoption

3.1.2. exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763

Vertex Pharmaceuticals (Ireland) Limited; treatment of transfusion-dependent β-thalassemia and sickle cell disease
Scope: Opinion
Action: For adoption

3.1.3. dabigatran etexilate - EMEA/H/C/005922

prevention of venous thromboembolic events
Scope: Opinion
Action: For adoption

3.1.4. eribulin - EMEA/H/C/006134

treatment of breast cancer and liposarcoma
Scope: Opinion
Action: For adoption

3.1.5. ibuprofen - EMEA/H/C/006129

Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age
Scope: Opinion

Action: For adoption


### 3.1.6. Pomalidomide - EMEA/H/C/006195

In combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Scope: Opinion

Action: For adoption


### 3.1.7. omaveloxolone - Orphan - EMEA/H/C/006084

Reata Ireland Limited; Treatment of Friedreich’s ataxia

Scope: Opinion

Action: For adoption


### 3.1.8. etrasimod - EMEA/H/C/006007

treatment of patients with moderately to severely active ulcerative colitis (UC)

Scope: Opinion

Action: For adoption


### 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

#### 3.2.1. concizumab - EMEA/H/C/005938

Routine prophylaxis to prevent or reduce the frequency of bleeding in patients with:
- haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors ≥ 12 years of age;
- haemophilia B (congenital factor IX deficiency) with FIX inhibitors of any age

Scope: List of outstanding issues

Action: For adoption

3.2.2. **apremilast - EMEA/H/C/006208**

- Treatment of psoriatic arthritis, psoriasis, Behçet’s disease
- Scope: List of outstanding issues
- **Action**: For adoption

3.2.3. **aumolertinib - EMEA/H/C/006069**

- Treatment of non-small cell lung cancer
- Scope: List of outstanding issues
- **Action**: For adoption
- List of Questions adopted on 30.03.2023.

3.2.4. **buprenorphine - EMEA/H/C/006188**

- Treatment of opioid drug dependence
- Scope: List of outstanding issues
- **Action**: For adoption
- List of Questions adopted on 22.06.2023.

3.2.5. **sugemalimab - EMEA/H/C/006088**

- Treatment of adults with metastatic non-small-cell lung cancer (NSCLC)
- Scope: List of outstanding issues
- **Action**: For adoption
- List of Questions adopted on 22.06.2023.

3.2.6. **serplulimab - Orphan - EMEA/H/C/006170**

- Henlius Europe GmbH; first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
- Scope: List of outstanding issues
- **Action**: For adoption

3.2.7. **aprocitentan - EMEA/H/C/006080**

- Treatment of resistant hypertension
- Scope: List of outstanding issues
- **Action**: For adoption
List of Questions adopted on 22.06.2023.

3.2.8. omecamtiv mecarbil - EMEA/H/C/006112

Treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%

Scope: List of outstanding issues

Action: For adoption


3.2.9. nintedanib - EMEA/H/C/006179

Treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) and lung diseases (ILDs) systemic sclerosis associated interstitial lung disease (SSc-ILD)

Scope: List of outstanding issues

Action: For adoption


3.2.10. ustekinumab - EMEA/H/C/006183

Treatment of Crohn’s disease and Ulcerative colitis, treatment of Crohn’s disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)

Scope: List of outstanding issues

Action: For adoption


3.2.11. flortaucipir (18F) - EMEA/H/C/006064

Indicated for Positron Emission Tomography (PET) imaging of the brain

Scope: List of outstanding issues

Action: For adoption


3.2.12. retilanlimab - Orphan - EMEA/H/C/006194

Incyte Biosciences Distribution B.V.; Treatment of Merkel cell carcinoma (MCC).

Scope: List of outstanding issues

Action: For adoption

3.3. **Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)**

3.3.1. **delgocitinib - EMEA/H/C/006109**

treatment of moderate to severe chronic hand eczema (CHE)
Scope: List of questions
**Action**: For adoption

3.3.2. **givinostat - Orphan - EMEA/H/C/006079**

Italfarmaco S.p.A.; treatment of Duchenne muscular dystrophy (DMD)
Scope: List of questions
**Action**: For adoption

3.3.3. **aztreonam / avibactam - EMEA/H/C/006113**

**Accelerated assessment**
treatment of infections (cIAI, HAP, VAP, and cUTI) and aerobic Gram-negative infections with limited treatment options
Scope: List of questions
**Action**: For adoption

3.3.4. **enzalutamide - EMEA/H/C/006299**

treatment of prostate cancer
Scope: List of questions
**Action**: For adoption

3.3.5. **insulin glargine - EMEA/H/C/006136**

treatment of diabetes mellitus
Scope: List of questions
**Action**: For adoption

3.3.6. **vilobelimab - EMEA/H/C/006123**

treatment of adult patients with SARS-CoV-2 induced septic acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).
Scope: List of questions
**Action**: For adoption
3.3.7. **trastuzumab - EMEA/H/C/006252**

is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and HER2 positive early breast cancer (EBC)

**Scope:** List of questions  
**Action:** For adoption

3.3.8. **avacincaptad pegol - EMEA/H/C/006153**

is indicated for the treatment of adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

**Scope:** List of questions  
**Action:** For adoption

3.3.9. **donanemab - EMEA/H/C/006024**

to slow disease progression in adult patients with Alzheimer’s disease (AD).

**Scope:** List of questions  
**Action:** For adoption

3.3.10. **temozolomide - Orphan - EMEA/H/C/006169**

Orphelia Pharma; treatment of neuroblastoma  
**Scope:** List of questions  
**Action:** For adoption

3.3.11. **zapomeran – OPEN – EMEA/H/C/006207**

active immunisation to prevent COVID-19  
**Scope:** List of questions  
**Action:** For adoption

3.3.12. **odronextamab - Orphan - EMEA/H/C/006215**

Regeneron Ireland Designated Activity Company; treatment of blood cancers (follicular lymphoma (FL) or diffuse large B cell lymphoma (DLBCL) and large B cell lymphoma)  
**Scope:** List of questions  
**Action:** For adoption

3.3.13. **lutetium (177Lu) chloride - EMEA/H/C/005882**

radiolabelling of carrier molecules, which have been specifically developed for radiolabelling with this radionuclide
3.3.14. ciclosporin - EMEA/H/C/006250

Treatment of dry eye disease in adult patients

Scope: List of questions
Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. catumaxomab - EMEA/H/C/005697

indicated for the treatment of malignant ascites

Scope: Letter by the applicant dated 22.11.2023 requesting an extension to the clock stop to respond to the list of questions adopted in December 2022.
Action: For adoption

3.4.2. methylphenidate hydrochloride - PUMA - EMEA/H/C/005975

treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over

Scope: Letter by the applicant dated 23.11.2023 requesting an extension to the clock stop to respond to the list of questions adopted in June 2023.
Action: For adoption
List of questions adopted on 22.06.2023.

3.4.3. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/006053

indicated for in vitro radiolabelling of specific carrier molecules to be used for positron emission tomography (PET) imaging

Scope: Letter by the applicant dated 30.11.2023 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in September 2023.
Action: For adoption

3.4.4. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165

indicated for in vitro labelling of kits for radiopharmaceutical preparation

Scope: Letter by the applicant dated 07.12.2023 requesting an extension to the responses to the list of outstanding issues adopted in October 2023.
**Action**: For adoption


### 3.4.5. polihexanide - Orphan - EMEA/H/C/005858

SIFI SPA; treatment of acanthamoeba keratitis

Scope: Letter by the applicant dated 06.12.2023 requesting an extension to the responses to the list of outstanding issues adopted in November 2023.

**Action**: For adoption


### 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

### 3.6. Initial applications in the decision-making phase

No items

### 3.7. Withdrawals of initial marketing authorisation application

No items

### 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

#### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

#### 4.1.1. Entyvio - vedolizumab - EMEA/H/C/002782/X/0075

Takeda Pharma A/S

Rapporteur: Paolo Gasparini

Scope: quality

**Action**: For adoption

4.1.2. Lumykras - sotorasib - EMEA/H/C/005522/X/0009

Amgen Europe B.V.
Rapporteur: Alexandre Moreau
Scope: “Extension application to add a new strength of 240 mg film-coated tablet.”

Action: For adoption
List of Questions adopted on 22.06.2023.

4.1.3. Viagra - sildenafil - EMEA/H/C/000202/X/0115

Upjohn EESV
Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Maria Concepcion Prieto Yerro
Scope: “Extension application to introduce a new pharmaceutical form (orodispersible film).”

Action: For adoption

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Teriflunomide Accord - teriflunomide - EMEA/H/C/005960/X/0002

Accord Healthcare S.L.U.
Rapporteur: Kristina Nadrah, PRAC Rapporteur: Martin Huber
Scope: “Extension application to add a new strength of 7 mg film-coated tablets. The bioequivalence study data were submitted.”

Action: For adoption

4.2.2. Kalydeco - ivacaftor - EMEA/H/C/002494/X/0115/G

Vertex Pharmaceuticals (Ireland) Limited
Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Monica Martinez Redondo
Scope: “Extension application to introduce a new strength (13.4 mg of ivacaftor granules in sachet), grouped with a type II variation (C.I.6.a) in order to extend the indication of the granule presentations to include children with cystic fibrosis aged 1 to less than 4 months of age and weighing 3 kg or more who have an R117H CFTR mutation or one of the approved 9 gating (class III) mutations based on interim results from study VX15-770-124 (study 124); this is a phase 3, 2-part, open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of ivacaftor (IVA) in subjects with CF who are less than 24 months
of age at treatment initiation and have a CFTR gating mutation. As a consequence, sections 1, 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3 and 8 of the SmPC of the granules presentations and sections 4.2, 4.8, 5.1 and 5.2 of the SmPC of the tablets presentations are updated. The Labelling for the 13.4 mg granule presentation and the Package Leaflet of the granules and tablets presentations are updated in accordance. Version 15.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.

Type IA A.5.b
Type IA B.II.b.2.a

**Action**: For adoption


### 4.2.3. Opdivo - nivolumab - EMEA/H/C/003985/X/0132

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Martin Huber

**Scope**: quality

**Action**: For adoption


### 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

#### 4.3.1. Edurant - rilpivirine - EMEA/H/C/002264/X/0042/G

Janssen-Cilag International N.V.

Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Liana Gross-Martirosyan

**Scope**: 
"Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg dispersible tablets). The new presentation is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in patients ≥2 to <18 years of age and weighing at least 10 kg to less than 25 kg. The PI and RMP have been updated in accordance.

Type II variation (C.I.6.a) to modify the approved therapeutic indication of the already authorised 25 mg film-coated tablets presentation to include, in combination with other antiretroviral medicinal products, treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve and virologically suppressed (HIV-1 RNA less than 50 copies per ml) paediatric patients from 2 to less than 12 years weighing at least 25 kg, based on final results from study studies TMC278-TiDP38-C213 Cohort 2. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. The updated RMP version 10.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to Annex II and to update the list of local representatives in the Package Leaflet."
**Action:** For adoption

### 4.3.2. Eliquis - apixaban - EMEA/H/C/002148/X/0089/G

Bristol-Myers Squibb / Pfizer EEIG

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to:
1) Introduce a new pharmaceutical form (granules in single-dose container) associated with a new strength (0.15 mg).
2) Introduce a new pharmaceutical form (coated granules in sachet) associated with 3 new strengths (0.5 mg, 1.5 mg and 2 mg).

The above two line extensions are grouped with a type II - C.1.6.a variation:
Extension of indication to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age for Eliquis (all strengths), based on a pre-specified interim analysis from study CV185325; this is an open-label, multi-centre, randomized, active controlled trial to provide PK data and data on anti-Xa activity to support the extrapolation of efficacy to children, to evaluate safety and efficacy of apixaban in children who require anticoagulation for a venous thromboembolism; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPCs are updated. The Package Leaflet and Annex II are updated in accordance. Version 21.0 of the RMP has also been submitted."

**Action:** For adoption

### 4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

#### 4.4.1. Reagila - Cariprazine - EMEA/H/C/002770/X/0033

Gedeon Richter Plc.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension application to introduce a new pharmaceutical form (orodispersible tablets). The RMP (version 3.0) is updated in accordance."

Change of timetable to respond to the list of questions adopted in November 2023.

**Action:** For adoption

List of Questions adopted on 09.11.2023.

### 4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items
5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0012

Pfizer Europe MA EEIG

Rapporteur: Daniela Philadelphia, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include infants, children and adolescents from 6 weeks to less than 18 years of age for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae, based on final results from studies B7471003, B7471011, B7471012, B7471013 and B7471014. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted."

Action: For adoption


5.1.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - ATMP - EMEA/H/C/005095/II/0021

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: "Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD and a PI, have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomized, open-label, multicentre study to determine whether treatment with cilta-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI. As part of the application the MAH is requesting a 1-year extension of the market protection."

Action: For adoption

Request for Supplementary Information adopted on 08.09.2023.
5.1.3. Cibinqo - abrocitinib - EMEA/H/C/005452/II/0010

Pfizer Europe MA EEIG
Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: "Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis for CIBINQO based on final results from non-clinical study 00655292 [21GR211] and interim results from clinical study B7451015; this is a Phase III multi-centre, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted."

Action: For adoption

5.1.4. Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320/II/0016

Sanofi Winthrop Industrie
Rapporteur: Fátima Ventura, PRAC Rapporteur: Liana Gross-Martirosyan
Scope: "Extension of indication to include treatment of both first stage (haemo-lymphatic) and second stage (meningo-encephalitic) of human African trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense for FEXINIDAZOLE WINTHROP based final results from study DNDI-FEX-07-HAT - Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicentre, open-label clinical trial; this is a phase-II/III, multicenter, open-label, non-randomized, single-arm clinical trial to assess the efficacy and safety of fexinidazole in patients with r-HAT. As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted."

Action: For adoption

5.1.5. HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0087

Baxalta Innovations GmbH
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer
Scope: "Extension of indication to include treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults for HyQvia, based on final results from studies 161403 and ABV-771-1001; and interim results from study 161505. 161403 and 161505 are interventional Phase III efficacy and safety studies respectively, while ABV-771-1001 is an interventional Phase I safety study. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 14.0 of the RMP has also been submitted."

Action: For adoption
5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0134

Merck Sharp & Dohme B.V.

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant, treatment of resectable stage II, IIIA, or IIIB (T3 4N2) non-small cell lung carcinoma in adults for Keytruda based on study KEYNOTE-671, a phase III, randomized, double-blind trial of platinum doublet chemotherapy +/- pembrolizumab as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 41.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023.

5.1.7. Kisqali - ribociclib - EMEA/H/C/004213/II/0045

Novartis Europharm Limited

Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage II or stage III early breast cancer, irrespective of nodal status, in combination with an AI for Kisqali based on study CLEE011O12301C (NATALEE); This is a global, Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with ET versus ET alone as adjuvant treatment in patients with HR-positive, HER2-negative, early breast cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

5.1.8. LIVMARLI - maralixibat - Orphan - EMEA/H/C/005857/II/0003/G

Mirum Pharmaceuticals International B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Adam Przybylkowski

Scope: "Grouped variation consisting of:
1) Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 2 months of age and older for LIVMARLI, based on results from studies MRX-502, LUM001-501, MRX-503, MRX-800 and MRX-801; MRX-502 is an international, multicenter, randomized, double-blind, placebo-controlled, parallel group Phase 3 study that evaluated the efficacy and safety of maralixibat in PFIC participants aged >12 months to <18 years on a proposed dosage of up to 600 μg/kg BID over 6 months. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Annex II are updated in accordance. Version 2.0 of the
RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes.

2) B.I.b.1.b” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption


5.1.9. **Metalyse - Tenecteplase - EMEA/H/C/000306/II/0070/G**

Boehringer Ingelheim International GmbH

Rapporteur: Martina Weise

Scope: "Grouped application consisting of:
C.I.6.a (Type II): To add the new therapeutic indication Acute Ischemic Stroke (AIS) for the new 25 mg presentation. Consequently, a separate SmPC and Package Leaflet are provided for the 25 mg presentation with the new indication. In addition, the MAH took the opportunity to implement editorial changes and minor updates to the PI of Metalyse 40 mg (8,000 U) and 50 mg (10,000 U).
B.II.e.5.c (Type II): To add the new 25 mg presentation for the sterile parenteral biological medicinal product Metalyse (tenecteplase) powder and solvent for solution for injection.
B.II.b.3.a
B.II.e.1.b.2”

**Action**: For adoption

Request for Supplementary Information adopted on 09.11.2023.

5.1.10. **Palforzia - defatted powder of arachis hypogaea L., semen (peanuts) - EMEA/H/C/004917/II/0014/G**

Aimmune Therapeutics Ireland Limited

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kirsti Villikka

Scope: "Grouped variation consisting of:
C.1.6.a (Extension of indication): Extension of indication to include treatment of patients 1 to 3 years old for PALFORZIA, based on final results from study ARC005; this is a Phase 3 randomized, double-blind, placebo-controlled Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) to evaluate the safety and efficacy of peanut powder in terms of superiority of placebo in children of 1 year to less than 4 years of age with peanut allergy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 6.5 and 8 of the SmPC are updated. The Package Leaflet and Labelling were updated accordingly. Version 1.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the SmPC and to update the list of local representatives in the Package Leaflet. As part of the application the MAH is requesting a 1-year extension of the market protection.
B.II.e.5.a: Introduction of a new pack-size of 16 capsules of 1 mg (Level 0) in blisters for PALFORZIA, 1 mg, oral powder in capsules for opening.
Due to the lack of a suitable pack-size for the up-dosing phase for patients 1 to 3 years old, a new pack size Level 0 for the up-dosing phase will be introduced. Labelling was updated accordingly.” Request for 1 year of market protection for a new indication (Article 14(11) of
5.1.11. **SCENESSE - afamelanotide - Orphan - EMEA/H/C/002548/II/0044**

Clinuvel Europe Limited

Rapporteur: Janet Koenig, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication for the prevention of phototoxicity in adolescent patients (12 to under 18 years of age) with erythropoietic protoporphyria (EPP), based on the analysis of the safety and efficacy data available. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.4 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce a minor editorial correction to the PI."

Action: For adoption

**5.1.12. TAGRISSO - osimertinib - EMEA/H/C/004124/II/0053**

AstraZeneca AB

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include TAGRISSO in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, based on final results from study FLAURA2 (DS169C00001); this is a Phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, multicentre study to assess the efficacy and safety of TAGRISSO as first-line treatment in patients with EGFR mutation-positive, locally advanced or metastatic NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 16 of the RMP has also been submitted."

Action: For adoption

**5.1.13. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0081**

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include, in combination with bevacizumab, adjuvant treatment of adult patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation for TECENTRIQ, based on final results from study WO41535 (IMbrave050); this is a phase III, randomized, multi-centre, international, open-label study, conducted to evaluate the efficacy and safety of adjuvant therapy of atezolizumab in combination with bevacizumab in patients with completely resected or ablated HCC who were at high risk for disease recurrence. As a consequence, sections 4.1, 4.2, 4.8 and 5.1
of the SmPC are updated. The Package Leaflet is updated in accordance. Version 28.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes.”

**Action:** For adoption

### 5.1.14. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0082

Roche Registration GmbH

**Rapporteur:** Aaron Sosa Mejia, PRAC **Rapporteur:** Ana Sofia Diniz Martins

**Scope:** "Extension of indication to include first-line treatment of adult patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy and who do not have EGFR mutant or ALK-positive disease, who have: locally advanced unresectable NSCLC not amenable for definitive chemoradiotherapy, or metastatic NSCLC, for TECENTRIQ, based on final results from study MO29872 (IPSOs); this is a phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (stage IIIb not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. Version 29.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

**Action:** For adoption

### 5.1.15. Valdoxan - agomelatine - EMEA/H/C/000915/II/0051

Les Laboratoires Servier

**Rapporteur:** Eva Skovlund, PRAC **Rapporteur:** Pernille Harg

**Scope:** "Extension of indication to include a new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depressive episodes, if depression is unresponsive to psychological therapy alone, for Valdoxan, further to the results of the phase 2 (CL2-20098-075) and phase 3 (CL3-20098-076) paediatric clinical studies included in the Paediatric Investigation Plan number EMEA-001181-PIP-11; As a consequence, the sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. The updated RMP version 25.1 has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 22.06.2023, 26.01.2023.

### 5.1.16. VeraSeal - human fibrinogen / human thrombin - EMEA/H/C/004446/II/0027

Instituto Grifols, S.A.

**Rapporteur:** Daniela Philadelphia, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC **Rapporteur:** Amelia Cupelli

**Scope:** "Extension of indication to include treatment of children for VeraSeal, based on final
results from study IG1405; this is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of VeraSeal as an adjunct to haemostasis during surgery in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted.”

**Action:** For adoption


---

### 5.1.17. Xtandi - enzalutamide - EMEA/H/C/002639/II/0063

**Astellas Pharma Europe B.V.**

Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Maria del Pilar Rayon

**Scope:** "Extension of indication to include treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy, for Xtandi, based on final results from study MDV3100-13 (EMBARK); this is a phase 3, randomized, efficacy and safety study of enzalutamide plus leuproide, enzalutamide monotherapy, and placebo plus leuproide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet."

**Action:** For adoption

---

### 5.1.18. Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0037

**Merck Sharp & Dohme B.V.**

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski

**Scope:** "Extension of indication to include treatment of the paediatric population (1 to 18 years of age) for ZINPLAVA, based on final results from study MK-6072-001 (MODIFY III) listed as a category 3 study in the RMP; this is a phase 3, randomised, placebo-controlled, parallel-group, multi-site, double-blind trial evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of a single infusion of bezlotoxumab in paediatric participants from 1 to <18 years of age receiving antibacterial drug treatment for Clostridioides difficile infection (CDI). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI."

**Action:** For adoption

Request for Supplementary Information adopted on 12.10.2023, 22.06.2023.
5.2. **Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

5.2.1. **CellCept - mycophenolate mofetil - EMEA/H/C/000082/II/0170/G**

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher

Scope: “C.I.6.a: Extension of indication to include paediatric patients (3 months to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 3 months, based on pharmacokinetic data, published literature and the Roche Global Safety Database. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Type IB (C.I.z): To update section 4.2 of the SmPC for the CellCept 500 mg tablets formulation in order to be in line with the other three CellCept formulations. And for alignment with the current QRD guidance, the Package Leaflet was updated to cross reference section 2 in section 6 for sodium content. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring the PI in line with the latest QRD template version 10.3.”

Request for an extension to the clock stop to respond to the request for supplementary information adopted in September 2023.

**Action**: For adoption


5.3. **Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

6. **Medical devices**

6.1. **Ancillary medicinal substances - initial consultation**

No items

6.2. **Ancillary medicinal substances – post-consultation update**

No items
6.3. **Companion diagnostics - initial consultation**

6.3.1. **In vitro diagnostic medical device - EMEA/H/D/006372**

next generation sequencing (NGS) assay for tumour mutation profiling

**Scope**: Opinion

**Action**: For adoption

Request for supplementary information adopted on 09.11.2023.

6.3.2. **In vitro diagnostic medical device - EMEA/H/D/006373**

detection of PD-L1 protein

**Scope**: Opinion

**Action**: For adoption

Request for supplementary information adopted on 09.11.2023, 12.10.2023.

6.3.3. **in vitro diagnostic medical device - EMEA/H/D/006341**

detection of the anaplastic lymphoma kinase (ALK) protein

**Scope**: Request for supplementary information

**Action**: For adoption

6.4. **Companion diagnostics – follow-up consultation**

No items

7. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

7.1. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

No items
8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. obecabtagene autoleucel - H0005907

Obecabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

Action: For adoption

8.1.2. Sipavibart - H0006291

Pre-exposure prophylaxis of COVID-19

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

Action: For adoption

8.1.3. lazertinib - H0006074

in combination with amivantamab is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

Action: For adoption

8.1.4. Dorocubicel/Allogeneic umbilical cord-derived CD34- cells, non-expanded – PRIME - H0005772

Treatment of adult patients with haematological malignancies requiring an allogeneic hematopoietic stem cell transplantation who lack a readily available suitable donor

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.
9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Bimervax - sars-cov-2 virus, variants b.1.351-b.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058/II/0004

Hipra Human Health S.L.

Rapporteur: Beata Maria Jakline Ullrich

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and immunogenicity information after a fourth dose based on interim results from study HIPRA-HH-2) listed as a category 3 study in the RMP; this is A Phase IIb, Double-Blind, Randomised, Active-Controlled, Multicentre, Non-Inferiority Trial Followed By A Phase III, Single-Arm, Open-Label Trial To Assess Immunogenicity And Safety Of A Booster Vaccination With A Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-COV-2 In Adults Fully Vaccinated Against Covid-19 Followed By An Extension Period To Study A Fourth Dose Administration Of PHH-1V. The Package Leaflet is updated accordingly. In addition, the MAH submitted the full user consultation with target patient groups."

Action: For adoption


9.1.2. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan

GlaxoSmithKline (Ireland) Limited

Scope: Renewal of conditional marketing authorisation, re-examination

Action: For adoption


See 2.2

9.1.3. LUMYKRAS - Sotorasib - EMEA/H/C/005522/II/0010/G

Amgen Europe B.V.

Rapporteur: Alexandre Moreau

Scope: "Update of sections 4.2, 4.4, 4.8, 5.2 and 5.3 of the SmPC in order to change in the recommended dose and to update safety and efficacy information based on results from study 20190009 (CodeBreaK 200) listed as a specific obligation in the Annex II, in order to fulfil SOB/001; and results from study 20170543 (CodeBreak 100) Phase 2 Part B. Study 20190009 is a Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C; while study 20170543 is a Phase 1/2, Open-label Study Evaluating the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update Annex II of the SmPC.”

**Action**: For adoption

Request for Supplementary Information adopted on 25.05.2023.

### 9.1.4 Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan

PTC Therapeutics International Limited

Scope: intervention by a third party

**Action**: For information


### 9.1.5 Tremelimumab AstraZeneca - tremelimumab - EMEA/H/C/004650/II/0002

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia

Scope: “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the paediatric information based on final results from study D419EC00001; this is a Phase I/II, open-label, multicenter study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors and hematological malignancies.”

Withdrawal of Type II variation procedure

**Action**: For information

### 9.1.6 Clopidogrel BGR (SRD) – clopidogrel – EMEA/H/C/001138

Laboratoires BIOGARAN; prevention of atherothrombotic events

Rapporteur: Alexandre Moreau

Scope: Withdrawal of marketing authorisation

**Action**: For information

### 9.1.7 Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0095

AstraZeneca AB

Rapporteur: Sol Ruiz

Scope: “Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update clinical information, following a critical evaluation of the benefit-risk profile of Vaxzevria against...”
currently circulating variants of concern based on available data and structured benefit risk assessment."

**Action:** For adoption

### 9.1.8. Holoclar - Ex vivo expanded autologous human corneal epithelial cells containing stem cells - EMEA/H/C/002450/R/0058, Orphan, ATMP

Holostem Terapie Avanzate s.r.l.

Rapporteur: Egbert Flory, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Eamon O Murchu

Scope: Switch to standard MA

**Action:** For adoption

Request for Supplementary Information adopted on 06.10.2023.

## 10. Referral procedures


### 10.1.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065

Orexigen Therapeutics Ireland Limited

Referral Rapporteur: Thalia Marie Estrup Blicher, Referral Co-Rapporteur: Daniela Philadelphy

Scope: List of outstanding issues, timetable

**Action:** For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of Mysimba (naltrexone/bupropion), taking into account any consequences from the failure to comply with the obligations laid down in the marketing authorisation.

This review of all available data on the potential long-term cardiovascular risk and its impact on the benefit-risk balance of Mysimba in its approved indication was considered needed in view of the remaining concern and lack of adequate study plan to address the uncertainty about this risk.

In addition, the EC requests the Agency/CHMP to give its opinion, as soon as possible, as to whether temporary measures are necessary to ensure the safe and effective use of this medicinal product.
10.2. **Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004**

No items

10.3. **Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004**

No items

10.4. **Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

10.4.1. **Ibuprofen NVT – ibuprofen - EMEA/H/A-29(4)/1533**

Laboratorios Liconsa, S.A.

Referral Rapporteur: TBC, Referral Co-Rapporteur: TBC

Scope: Appointment of rapporteurs, list of questions, timetable

**Action:** For adoption

Mutual Recognition Procedure number: LT/H/0162/002/E/001, notification sent by the Agency of Lithuania dated 17 November 2023 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

10.5. **Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

10.5.1. **Havrix – Hepatitis A virus (inactivated, adsorbed) - EMEA/H/A-30/1527**

GlaxoSmithKline Biologicals

Referral Rapporteur: Maria Grazia Evandri, Referral Co-Rapporteur: Lyubina Racheva

Scope: Revised timetable

**Action:** For adoption

Harmonisation exercise for Havrix and associated names. Product Information harmonisation was triggered by the MAH.


10.6.1. **Azithromycin containing medicinal products for systemic use – various – EMEA/H/A-31/1532**

MAH various (NAPs only)
Referral Rapporteur: Janet Koenig, Referral Co-Rapporteur: Maria Concepcion Prieto Yerro

Scope: Update of timetable (extension of clock-stop)

**Action:** For adoption

Need to re-evaluate the benefit-risk ratio of the approved indications considering the current scientific knowledge, the increasing resistance rate, the consumption data suggesting overuse and the different indications in the EU Member States. Furthermore, the appropriate dose and duration of administration for both oral and intravenous formulations need to be discussed as well as the adequacy of safety relevant information, information on pregnancy and breastfeeding and pharmacological properties.

The German National Competent Authority triggered a referral under Article 31 of Directive 2001/83 based on interest of the Union, requesting an opinion to CHMP on the benefit-risk of azithromycin-containing products and whether marketing authorisations of azithromycin-containing products for systemic use should be maintained, varied, suspended, or revoked.

Two requests were received from MAHs to extend the clock submission deadline for responses.

10.6.2. **Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529**

MAH various

Referral Rapporteur: Maria Concepcion Prieto Yerro, Referral Co-Rapporteur: Janet Koenig

Scope: List of outstanding issues / Opinion

**Action:** For adoption

Article 31 procedure triggered by the Agency of Medicines and Medical Devices (AEMPS) in Spain, concerning the contract research organisation (CRO) Synapse Labs Pvt. Ltd., located in Kharadi, Pune, India.

See 2.4


No items

10.8. **Procedure under Article 107(2) of Directive 2001/83/EC**

No items

10.9. **Disagreement between Member States on Type II variation–Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003**

No items
10.10. **Procedure under Article 29 of Regulation (EC) 1901/2006**

No items

10.11. **Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008**

No items

11. **Pharmacovigilance issue**

11.1. **Early Notification System**

December 2023 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action**: For information

12. **Inspections**

12.1. **GMP inspections**

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. **GCP inspections**

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. **Pharmacovigilance inspections**

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. **GLP inspections**

Information related to GLP inspections will not be published as it undermines the purpose of such inspections
13. **Innovation Task Force**

13.1. **Minutes of Innovation Task Force**

No items

13.2. **Innovation Task Force briefing meetings**

No items


No items

13.4. **Nanomedicines activities**

No items

14. **Organisational, regulatory and methodological matters**

14.1. **Mandate and organisation of the CHMP**

14.1.1. **Vote by proxy**

No items

14.2. **Coordination with EMA Scientific Committees**

14.2.1. **Pharmacovigilance Risk Assessment Committee (PRAC)**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for December 2023

**Action:** For adoption

14.2.2. **Paediatric Committee (PDCO)**

Agenda of the December 2023 PDCO plenary meeting

**Action:** For information

14.2.3. **Joint CHMP-CAT membership**

Nomination by CHMP of joint members to CAT. According to the ATMP Regulation, CAT
Committee for medicinal products for human use (CHMP)
EMA/CHMP/501322/2023

memorieship includes five members or co-opted members of the CHMP from five Member States, with alternates either proposed by their respective Member State or, in the case of co-opted members of the CHMP, identified by the latter on the advice of the corresponding co-opted member. The mandates for the current joint CHMP-CAT memberships will expire on 17.12.2023.

**Action:** For information

### 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

#### 14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry, Vice-chair: Francesca Luciani

Reports from BWP December 2023 meeting to CHMP for adoption:

- 21 reports on products in scientific advice and protocol assistance
- 11 reports on products in pre-authorisation procedures
- 5 reports on products in plasma master file

**Action:** For adoption

#### 14.3.2. Call for nomination of new member (BWP)

Following the resignation of a BWP member, a call for nomination of a new member is being launched. Applications should be sent by **11 January 2024**. The election of the new member will take place at the January plenary meeting.

**Action:** For information

#### 14.3.3. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 14-15 November 2023.

**Action:** For adoption

#### 14.3.4. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 27-30 November 2023. Table of conclusions

**Action:** For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.
14.3.5. **Call for interest for nomination of a replacement SAWP member**

Call for interest for nomination of a replacement SAWP member following departure of Nanna Borup Johansen.

Required areas of expertise: endocrinology/diabetes/metabolism, real-world evidence/pharmacoepidemiology.

Applications should be sent by **Thursday, 4 January 2024 EOB**. The new SAWP member and his/her alternate starting date will immediately follow their nomination by the CHMP PROM (15 January 2024).

**Action:** For information

14.3.6. **Nominations of PRAC and QRD representatives**

Following recent departure of their current SmPC AG representative, PRAC and QRD have nominated new representatives.

Nomination(s) received

**Action:** For endorsement

14.4. **Cooperation within the EU regulatory network**

No items

14.5. **Cooperation with International Regulators**

No items

14.6. **Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee**

No items

14.7. **CHMP work plan**

14.7.1. **CHMP Workplan 2024**

CHMP: Harald Enzmann

**Action:** For discussion/adoPTION

14.8. **Planning and reporting**

14.8.1. **Update of the Business Pipeline report for the human scientific committees**

Q4-2023 initial marketing authorisation application submissions with eligibility request to
central procedure.

**Action:** For information

### 14.9. Others

#### 14.9.1. CHMP Learnings

CHMP: Outi Mäki-Ikola

Collection, discussion and recording of CHMP learnings.

**Action:** For information

### 15. Any other business

#### 15.1. AOB topic

No items
Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

**Oral explanations (section 2)**

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

**Initial applications (section 3)**

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

![Evaluation Timeline](image)

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.
Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.
**Referral procedures (section 10)**

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

**Pharmacovigilance issues (section 11)**

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

**Inspections Issues (section 12)**

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Innovation task force (section 13)**

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

**Scientific advice working party (SAWP) (section 14.3.1)**

This section refers to the monthly report from the CHMP’s Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

**Satellite groups / other committees (section 14.2)**

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

**Invented name issues (section 14.3)**

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group’s main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)
Annex to 11-14 December 2023 CHMP Agenda
Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES ................................................................. 3
A.1. ELIGIBILITY REQUESTS ................................................................. 3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications .................................. 3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION ........................................ 3

B. POST-AUTHORISATION PROCEDURES OUTCOMES .......................... 3
B.1. Annual re-assessment outcomes ........................................................ 3
B.1.1. Annual reassessment for products authorised under exceptional circumstances ...... 3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES .............. 4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal .............................. 4
B.2.2. Renewals of Marketing Authorisations for unlimited validity ................................ 4
B.2.3. Renewals of Conditional Marketing Authorisations .......................................... 4
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES ...................... 5
B.4. EPARs / WPARs ........................................................................ 8
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES ............... 9
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects ................................. 9
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .................. 18
B.5.3. CHMP-PRAC assessed procedures .............................................................. 34
B.5.4. PRAC assessed procedures ........................................................................... 39
B.5.5. CHMP-CAT assessed procedures ................................................................. 45
B.5.6. CHMP-PRAC-CAT assessed procedures ......................................................... 46
B.5.7. PRAC assessed ATMP procedures ................................................................. 46
B.5.8. Unclassified procedures and worksharing procedures of type I variations ............... 46
B.5.9. Information on withdrawn type II variation / WS procedure ............................... 48
B.5.10. Information on type II variation / WS procedure with revised timetable ............. 49
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION .................. 49
B.6.1. Start of procedure for New Applications: timetables for information .................. 49
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information .......................................................... 50
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information ............................................................................................................. 50
B.6.4. Annual Re-assessments: timetables for adoption ........................................ 51
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed ................................................................. 51
B.6.6. VARIATIONS – START OF THE PROCEDURE ................................................. 52
B.6.7. Type II Variations scope of the Variations: Extension of indication ................ 52
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects .......................... 55
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .......... 59
B.6.10. CHMP-PRAC assessed procedures ................................................................ 72
B.6.11. PRAC assessed procedures ......................................................................... 76
B.6.12. CHMP-CAT assessed procedures .................................................................. 83
B.6.13. CHMP-PRAC-CAT assessed procedures ....................................................... 83
B.6.14. PRAC assessed ATMP procedures ................................................................ 83
B.6.15. Unclassified procedures and worksharing procedures of type I variations .... 83
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY ..................... 85
B.7.1. Yearly Line listing for Type I and II variations .................................................. 85
B.7.2. Monthly Line listing for Type I variations ....................................................... 85
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) .............................. 85
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) .................................................. 85
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) .......................................................... 85
B.7.6. Notifications of Type I Variations (MMD only) ............................................... 85

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) ................................... 85

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) ......................................................................................... 85

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES ............... 85
E.1. PMF Certification Dossiers .................................................................................. 85
E.2. Time Tables – starting & ongoing procedures: For information ....................... 85

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver .... 85

G. ANNEX G ........................................................................................................... 85
G.1. Final Scientific Advice (Reports and Scientific Advice letters): ....................... 85
G.2. PRIME ............................................................................................................. 86

H. ANNEX H - Product Shared Mailboxes – e-mail address ............................. 86
A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for
December 2023: For adoption

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for
December 2023: For adoption

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Brineura - Cerliponase alfa -
EMEA/H/C/004065/S/0042, Orphan
BioMarin International Limited, Rapporteur: Martina Weise, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Mari Thorn

IMVANEX - Smallpox vaccine (live modified vaccinia virus Ankara) -
EMEA/H/C/002596/S/0095
Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer

Increlex - Mecasermin -
EMEA/H/C/000704/S/0081
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka

Lojuxta - Lomitapide -
EMEA/H/C/002578/S/0057
Amryt Pharmaceuticals DAC, Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst

Strensiq - Asfotase alfa -
EMEA/H/C/003794/S/0066, Orphan
Alexion Europe SAS, Rapporteur: Paolo
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

**Ambrisentan Mylan - Ambrisentan -**
EMEA/H/C/004985/R/0009
Mylan Pharmaceuticals Limited, Generic,
Generic of Volibris, Rapporteur: Anastasia
Mountaki, PRAC Rapporteur: Maria del Pilar
Rayon

**Doptelet - Avatrombopag -**
EMEA/H/C/004722/R/0018
Swedish Orphan Biovitrum AB (publ),
Rapporteur: Aaron Sosa Mejia, Co-Rapporteur:
Daniela Philadelphia, PRAC Rapporteur: Monica
Martinez Redondo

**Esperoct - Turoctocog alfa pegol -**
EMEA/H/C/004883/R/0022
Novo Nordisk A/S, Rapporteur: Daniela
Philadelphia, Co-Rapporteur: Ewa Balkowiec
Iskra, PRAC Rapporteur: Gabriele Maurer

**Grasustek - Pegfilgrastim -**
EMEA/H/C/004556/R/0014
Juta Pharma GmbH, Rapporteur: Karin Janssen
van Doorn, Co-Rapporteur: Martina Weise,
PRAC Rapporteur: Menno van der Elst

B.2.3. Renewals of Conditional Marketing Authorisations

**Blenrep - Belantamab mafodotin -**  Re-examination
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 27-30 November 2023 PRAC:
**Signal of drug reaction with eosinophilia and systemic symptoms (DRESS)**

Pirfenidone – Esbriet, Pirfenidone Axumio, Pirfenidone Viatris (CAP)

Rapporteur: multiple, Co-Rapporteur: multiple, PRAC Rapporteur: Rhea Fitzgerald

PRAC recommendation on a variation

**Action:** For adoption

---

**Signal of progressive multifocal leukoencephalopathy (PML)**

Axicabtagene Ciloleucel – Yescarta (CAP)

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, PRAC Rapporteur: Karin Ernholm

PRAC recommendation on a variation

**Action:** For adoption

---

**Signal of peripheral neuropathy**

Dabrafenib, Trametinib – Tafinlar, Mekinist (CAP)

Rapporteur: multiple, Co-Rapporteur: multiple, PRAC Rapporteur: David Olsen

PRAC recommendation on a variation

**Action:** For adoption

---

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its December 2023 meeting:

**EMEA/H/C/PSUSA/00001210/202304**
(emtricitabine / tenofovir disoprixil)

CAPS:
**Truvada** (EMEA/H/C/000594) (Emtricitabine / Tenofovir disoprixil), Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC
Rapporteur: Ana Sofia Diniz Martins, “01/04/2020 To: 01/04/2023”

**EMEA/H/C/PSUSA/00001363/202304**
(fenofibrate / pravastatin)

CAPS:
**Pravafenix** (EMEA/H/C/001243) (Fenofibrate / Pravastatin sodium), Laboratoires SMB s.a., Rapporteur: Jean-Michel Race, PRAC
Rapporteur: Nathalie Gault, “14/04/2021 To: 14/04/2023”
EMEA/H/C/PSUSA/00002314/202303
(parecoxib)
CAPS: Dynastat (EMEA/H/C/000381) (Parecoxib), Pfizer Europe MA EEIG, Rapporteur: Finbarr Leacy, PRAC Rapporteur: Rhea Fitzgerald, "01/04/2022 To: 31/03/2023"

EMEA/H/C/PSUSA/00002840/202303
(tacrolimus (topical formulations))
CAPS: Protopic (EMEA/H/C/000374) (Tacrolimus), LEO Pharma A/S, Rapporteur: Finbarr Leacy
NAPS: NAPs - EU
PRAC Rapporteur: Rhea Fitzgerald, "01/04/2021 To: 31/03/2023"

EMEA/H/C/PSUSA/00002892/202303
(tenofovir disoproxil)
CAPS: Viread (EMEA/H/C/000419) (Tenofovir disoproxil), Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault, "01/04/2020 To: 31/03/2023"

EMEA/H/C/PSUSA/00010213/202304
(delamanid)
CAPS: Deltyba (EMEA/H/C/002552) (Delamanid), Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jo Robays, "26/10/2022 To: 26/04/2023"

EMEA/H/C/PSUSA/00010644/202305
(atezolizumab)
CAPS: Tecentriq (EMEA/H/C/004143) (Atezolizumab), Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ana Sofia Diniz Martins, "17/05/2022 To: 17/05/2023"

EMEA/H/C/PSUSA/00010723/202304
(durvalumab)
CAPS: Imfinzi (EMEA/H/C/004771) (Durvalumab), AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: David Olsen, "01/05/2022 To: 30/04/2023"
EMEA/H/C/PSUSA/00010868/202304
(ivacaftor / tezacaftor / elexacaftor)
CAPS:
Kaftrio (EMEA/H/C/005269) (Ivacaftor / Tezacaftor / Elexacaftor), Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber, “21/10/2022 To: 20/04/2023”

EMEA/H/C/PSUSA/00011035/202305
(SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant)
CAPS:
VidPrevtyn Beta (EMEA/H/C/005754) (SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant), Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jana Lukacisinova, “09/11/2022 To: 09/05/2023”

EMEA/H/C/PSUSA/00011038/202304
(tremelimumab)
CAPS:
IMJUDO (EMEA/H/C/006016) (Tremelimumab), AstraZeneca AB,
Rapporteur: Aaron Sosa Mejia
Tremelimumab AstraZeneca (EMEA/H/C/004650) (Tremelimumab), AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: David Olsen, “21/10/2022 To: 20/04/2023”

B.4. EPARs / WPARs

Azacitidine Kabi - Azacitidine - EMEA/H/C/006154
For information only. Comments can be sent to the PL in case necessary.
Fresenius Kabi Deutschland GmbH, Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), Generic, Generic of Vidaza, Generic application (Article 10(1) of Directive No 2001/83/EC)

Krazati - Adagrasib - EMEA/H/C/006013
For information only. Comments can be sent to the PL in case necessary.
Mirati Therapeutics B.V., treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, New active substance (Article 8(3) of Directive No 2001/83/EC)

Naveruclif - Paclitaxel - EMEA/H/C/006173
For information only. Comments can be sent to the PL in case necessary.
Accord Healthcare S.L.U., treatment of
metastatic breast cancer, Generic, Generic of Abraxane, Generic application (Article 10(1) of Directive No 2001/83/EC)

**Omijara - Momelotinib** -
**EMEA/H/C/005768, Orphan**
GlaxoSmithKline Trading Services Limited, treatment of disease-related splenomegaly or symptoms and anaemia, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Rimmyrah - Ranibizumab** -
**EMEA/H/C/006055**
QILU PHARMA SPAIN S.L., treatment of neovascular age-related macular degeneration (AMD), Similar biological application (Article 10(4) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Rystiggo - Rozanolixizumab** -
**EMEA/H/C/005824, Orphan**
UCB Pharma, Treatment of generalised myasthenia gravis (gMG), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Spexotras - Trametinib** -
**EMEA/H/C/005886, Orphan**
Novartis Europharm Limited, treatment of paediatric patients aged 1 year and older with glioma, Known active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Uzpruvo - Ustekinumab** -
**EMEA/H/C/006101**
STADA Arzneimittel AG, treatment of plaque psoriasis, arthritis psoriatic, Crohn’s Disease and ulcerative colitis, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES**

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

**B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects**

**Abiraterone Krka - Abiraterone acetate** -
**EMEA/H/C/005649/II/0004**
KRKA, d.d., Novo mesto, Generic, Generic of Zytiga, Rapporteur: Andreja Kranjc

**Abrysvo - Respiratory syncytial virus vaccine (bivalent, recombinant)** -
**EMEA/H/C/006027/II/0001**
Pfizer Europe Ma EEIG, Rapporteur: Jayne Crowe

**Adjupanrix - Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)** -  
**EMEA/H/C/001206/II/0086/G**  
GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Patrick Vrijlandt  

**BIMERVAX - SARS-CoV-2 virus, variants**  
**B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer** -  
**EMEA/H/C/006058/II/0005/G**  
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich  

**BIMERVAX - SARS-CoV-2 virus, variants**  
**B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer** -  
**EMEA/H/C/006058/II/0007/G**  
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich  
Request for Supplementary Information adopted on 16.11.2023, 05.10.2023.

**Bimzelx - Bimekizumab** -  
**EMEA/H/C/005316/II/0023/G**  
UCB Pharma S.A., Rapporteur: Finbarr Leacy

**Briumvi - Ublituximab** -  
**EMEA/H/C/005914/II/0003**  
Neuraxpharm Pharmaceuticals S.L., Rapporteur: Ewa Balkowiec Iskra  

**Cerezyme - Imiglucerase** -  
**EMEA/H/C/000157/II/0131**  
Sanofi B.V., Rapporteur: Patrick Vrijlandt

**COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified)** -  
**EMEA/H/C/005735/II/0192**  
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

**Cosentyx - Secukinumab** -  
**EMEA/H/C/003729/II/0107**
Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola
Request for Supplementary Information adopted on 09.11.2023.

**CRYSVITA - Burosumab -**  
**EMEA/H/C/004275/II/0035/G, Orphan**  
Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Gabriele Maurer  
Request for Supplementary Information adopted on 06.07.2023.

**Positive Opinion adopted by consensus on 30.11.2023.**

**Darunavir Mylan - Darunavir -**  
**EMEA/H/C/004068/II/0021**  
Mylan Pharmaceuticals Limited, Generic, Generic of Prezista, Rapporteur: John Joseph Borg  
Request for Supplementary Information adopted on 31.08.2023.

**Positive Opinion adopted by consensus on 30.11.2023.**

**DaTSCAN - Ioflupane (123I) -**  
**EMEA/H/C/000266/II/0066/G**  
GE Healthcare B.V., Rapporteur: Alexandre Moreau  

**Positive Opinion adopted by consensus on 16.11.2023.**

**Diacomit - Stiripentol -**  
**EMEA/H/C/000664/II/0045/G**  
BIOCDEX, Rapporteur: Alar Irs  
Request for Supplementary Information adopted on 23.11.2023.

**Request for supplementary information adopted with a specific timetable.**

**Elaprase - Idursulfase -**  
**EMEA/H/C/000700/II/0109**  
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Patrick Vrijlandt  
Request for Supplementary Information adopted on 31.08.2023, 25.05.2023.

**Entyvio - Vedolizumab -**  
**EMEA/H/C/002782/II/0079/G**  
Takeda Pharma A/S, Rapporteur: Paolo Gasparini  
Request for Supplementary Information adopted on 31.08.2023.

**Flucelvax Tetra - Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) -**  
**EMEA/H/C/004814/II/0041**
<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA Number</th>
<th>Company</th>
<th>Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibandronic Acid Teva - Ibandronic acid</td>
<td>EMEA/H/C/001195/II/0021</td>
<td>Teva B.V., Generic, Generic of Bondronat, Bonviva</td>
<td>Hrefna Gudmundsdottir</td>
</tr>
<tr>
<td>Ilumetri - Tildrakizumab</td>
<td>EMEA/H/C/004514/II/0052</td>
<td>Almirall S.A</td>
<td>Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Kalydeco - Ivacaftor</td>
<td>EMEA/H/C/002494/II/0120/G</td>
<td>Vertex Pharmaceuticals (Ireland) Limited</td>
<td>Maria Concepcion Prieto Yerro</td>
</tr>
<tr>
<td>Keytruda - Pembrolizumab</td>
<td>EMEA/H/C/003820/II/0143</td>
<td>Merck Sharp &amp; Dohme B.V., Rapporteur: Paolo Gasparini</td>
<td></td>
</tr>
<tr>
<td>MINJUVI - Tafasitamab</td>
<td>EMEA/H/C/005436/II/0012/G, Orphan</td>
<td>Incyte Biosciences Distribution B.V., Rapporteur: Aaron Sosa Mejia</td>
<td></td>
</tr>
<tr>
<td>Product Name</td>
<td>EMA/H/C/ID/II/ID</td>
<td>Company/Reporteur</td>
<td>Status</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Opzelura - Ruxolitinib</td>
<td>EMEA/H/C/005843/II/0002/G</td>
<td>Incyte Biosciences Distribution B.V., Rapporteur: Peter Mol</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
</tr>
<tr>
<td>Ovalleap - Follitropin alfa</td>
<td>EMEA/H/C/002608/II/0039</td>
<td>Theramex Ireland Limited, Rapporteur: Patrick Vrijlandt</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
</tr>
<tr>
<td>Ovitrelle - Choriogonadotropin alfa</td>
<td>EMEA/H/C/ID/ID</td>
<td></td>
<td>Positive Opinion adopted by consensus on</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merck Europe B.V., Rapporteur: Patrick Vrijlandt</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Pluvicto - Lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483/II/0010</strong></th>
<th>05.10.2023.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Europharm Limited, Rapporteur: Janet Koenig</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Polivy - Polatuzumab vedotin - EMEA/H/C/004870/II/0026, Orphan</strong></th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Registration GmbH, Rapporteur: Alexandre Moreau</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanofi Winthrop Industrie, Rapporteur: Patrick Vrijlandt</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Agios Netherlands B.V., Rapporteur: Alexandre Moreau</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gedeon Richter Plc., Rapporteur: Patrick Vrijlandt</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gedeon Richter Plc., Rapporteur: Patrick Vrijlandt</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ryzodeg - Insulin aspart / Insulin degludec - EMEA/H/C/002499/II/0054</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Name</td>
<td>Summary</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>(recombinant, adjuvanted)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/004336/II/0069</strong></td>
<td></td>
</tr>
<tr>
<td>GlaxoSmithKline Biologicals SA, Rapporteur: Christophe Focke</td>
<td></td>
</tr>
<tr>
<td><strong>Soliris - Eculizumab</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/000791/II/0128/G, Orphan</strong></td>
<td></td>
</tr>
<tr>
<td>Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez</td>
<td></td>
</tr>
<tr>
<td><strong>Spikevax - COVID-19 mRNA vaccine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>(nucleoside-modified)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/005791/II/0116/G</strong></td>
<td></td>
</tr>
<tr>
<td>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
</tr>
<tr>
<td><strong>Suliqua - Insulin glargine / Lixisenatide</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/004243/II/0037/G</strong></td>
<td></td>
</tr>
<tr>
<td>Sanofi Winthrop Industrie, Rapporteur: Kristina Dunder</td>
<td></td>
</tr>
<tr>
<td><strong>Surgiflo Haemostatic Matrix Kit - Human thrombin - EMEA/H/D/002301/II/0036/G</strong></td>
<td></td>
</tr>
<tr>
<td>Ferrosan Medical Devices A/S, Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
</tr>
<tr>
<td><strong>TachoSil - Human thrombin / Human fibrinogen</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/000505/II/0125/G</strong></td>
<td></td>
</tr>
<tr>
<td>Corza Medical GmbH, Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
</tr>
<tr>
<td><strong>Toujeo - Insulin glargine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/000309/II/0127/G</strong></td>
<td></td>
</tr>
<tr>
<td>Sanofi-Aventis Deutschland GmbH, Duplicate, Duplicate of Lantus, Rapporteur: Patrick Vrijlandt</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted on 09.11.2023.</td>
<td></td>
</tr>
<tr>
<td><strong>Tresiba - Insulin degludec</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EMEA/H/C/002498/II/0060</strong></td>
<td></td>
</tr>
<tr>
<td>Novo Nordisk A/S, Rapporteur: Kristina Dunder</td>
<td></td>
</tr>
<tr>
<td><strong>TRODELVY - Sacituzumab govitecan</strong></td>
<td>Request for supplementary information adopted with a specific timetable.</td>
</tr>
<tr>
<td><strong>EMEA/H/C/005182/II/0029</strong></td>
<td></td>
</tr>
<tr>
<td>Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted</td>
<td></td>
</tr>
<tr>
<td>Product Name</td>
<td>EMEA Reference</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Xofigo - Radium-223</td>
<td>EMEA/H/C/002653/II/0053</td>
</tr>
<tr>
<td>Yselty - Linzagolix choline</td>
<td>EMEA/H/C/005442/II/0009</td>
</tr>
</tbody>
</table>
**Zejula - Niraparib**  
**EMEA/H/C/004249/II/0046/G, Orphan**  
GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang

**Ziextenzo - Pegfilgrastim**  
**EMEA/H/C/004802/II/0030/G**  
Sandoz GmbH, Rapporteur: Christian Gartner  
Request for Supplementary Information adopted on 23.11.2023.

**WS2362**  
**Edistride**  
**EMEA/H/C/004161/WS2362/0057**  
**Forxiga**  
**EMEA/H/C/002322/WS2362/0078**  
AstraZeneca AB, Lead Rapporteur: Kristina Dunder  
Request for Supplementary Information adopted on 19.01.2023.

**WS2507**  
**Bondronat**  
**EMEA/H/C/000101/WS2507/0092**  
**Bonviva**  
**EMEA/H/C/000501/WS2507/0076**  
Atnahs Pharma Netherlands B.V., Lead Rapporteur: Thalia Marie Estrup Blicher  
Request for Supplementary Information adopted on 07.09.2023, 06.07.2023.

**WS2525/G**  
**Hexacima**  
**EMEA/H/C/002702/WS2525/0151/G**  
**Hexyon**  
**EMEA/H/C/002796/WS2525/0155/G**  
**MenQuadfi**  
**EMEA/H/C/005084/WS2525/0025/G**  
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus  
Request for Supplementary Information adopted on 07.09.2023.

**WS2574**  
**Nilemdo**  
**EMEA/H/C/004958/WS2574/0033**  
**Nustendi**  
**EMEA/H/C/004959/WS2574/0037**  
Daiichi Sankyo Europe GmbH, Lead Rapporteur:  
Request for supplementary information adopted with a specific timetable.
WS2575
Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-
EMEA/H/W/005362/WS2575/0009
Qdenga-
EMEA/H/C/005155/WS2575/0010
Takeda GmbH, Lead Rapporteur: Sol Ruiz

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Alkindi - Hydrocortisone -
EMEA/H/C/004416/II/0019
Diurnal Europe BV, Rapporteur: Karin Janssen van Doorn, "Update of section 4.2 of the SmPC in order to update posology recommendations in case of incomplete dosing, following the request by PRAC in the AR for procedure PSUSA/00010674/202208; the Package Leaflet is updated accordingly."

Ameluz - 5-aminolevulinic acid -
EMEA/H/C/002204/II/0055
Biofrontera Bioscience GmbH, Rapporteur: Janet Koenig, "Update of sections 4.2, 4.8, 5.1 and 6.6 of the SmPC in order to include artificial daylight lamps as an additional light source for photodynamic therapy in combination with Ameluz for the treatment of actinic keratoses based on final results from non-clinical study PT-0042-A and literature (investigator-initiator trials). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."
Request for Supplementary Information adopted on 12.10.2023, 25.05.2023.

BIMERVAX - SARS-CoV-2 virus, variants B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer -
EMEA/H/C/006058/II/0004
See 9.1

Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and immunogenicity information after a fourth dose based on interim results from study HIPRA-HH-2) listed as a category 3 study in the RMP; this is A Phase IIb, Double-Blind, Randomised,
Active -Controlled, Multicentre, Non-Inferiority Trial Followed By A Phase III, Single-Arm, Open-Label Trial To Assess Immunogenicity And Safety Of A Booster Vaccination With A Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-COV-2 In Adults Fully Vaccinated Against Covid-19 Followed By An Extension Period To Study A Fourth Dose Administration Of PHH-1V. The Package Leaflet is updated accordingly. In addition, the MAH submitted the full user consultation with target patient groups.”


**BIMERVAX - SARS-CoV-2 virus, variants B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer -**

EMEA/H/C/006058/II/0006

Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Submission of the final report from study HAN-01 listed as a category 3 study in the RMP (MEA/006). This is a phase IIb, randomised, controlled, observer-blinded study to evaluate safety and immunogenicity of a recombinant protein RBD fusion dimer candidate vaccine against SARS-CoV-2 in adult healthy volunteers.”


**Braftovi - Encorafenib -**

EMEA/H/C/004580/II/0031

Pierre Fabre Medicament, Rapporteur: Janet Koenig, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information on effect of encorafenib in combination with binimetinib on the single oral dose PK of specific CYP isozymes substrates, and effect of multiple doses of modafinil, a moderate CYP3A4 inducer, on the multiple oral dose PK of encorafenib administered with binimetinib based on final results from arm 1 and 3 of clinical study ARRAY-818-103/C4221003 (REC). ARRAY-818-103/C4221003 study is a Phase 1, 3-arm, open-label DDI study in patients with BRAF V600-mutant unresectable or metastatic melanoma or other BRAF V600-E and/or K-mutant advanced solid tumours.”

Request for Supplementary Information adopted
Drovelis - Drospirenone / Estetrol -
EMEA/H/C/005336/II/0021

Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder,
"Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding hepatic impairment based on final results from study MIT-Do001-C102; this is a Phase 1, open-label, parallel group, single-dose study to evaluate the pharmacokinetics and safety of estetrol (E4) in subjects with varying degrees of hepatic function."

Dupixent - Dupilumab -
EMEA/H/C/004390/II/0078

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.2 of the SmPC in order to allow the use of the Dupixent Prefilled Pen presentations for patients aged 2 to < 12 years of age based on final results of the R668-AD-1434 sub-study; this is an interventional open-label sub-study which purpose is to evaluate the PK, safety, immunogenicity, and efficacy of repeat doses of dupilumab (200 mg Q4W, 300 mg Q4W, and 200 mg Q2W) administered SC using a PFP with a skin pinch in children ≥2 to <12 years of age. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Epidyolex - Cannabidiol -
EMEA/H/C/004675/II/0028/G, Orphan

Jazz Pharmaceuticals Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher,
"Grouped application comprising three type II variations (C.I.13) as follows:
- Submission of the final report from study GWTX21068 – Genotoxicity study with 7-OH-CBD (Bacterial Reverse Mutation Assay). The objective of this study was to evaluate the ability of GWP4200370 (also known as 7-COOH-CBD) to induce reverse mutations in five histidine-requiring strains of Salmonella typhimurium in the absence and presence of a rat liver metabolizing system (S-9).
- Submission of the final report from study GWTX21028 – Genotoxicity study with 7-COOH-CBD (Bacterial Reverse Mutation Assay). The

Request for supplementary information adopted with a specific timetable.
Objective of this study was to evaluate the ability of GWP4200307 to induce reverse mutations in five histidine-requiring strains of Salmonella typhimurium in the absence and presence of a rat liver metabolizing system (S-9).

- Submission of the final report from GWTX18015 – Genotoxicity study with 7-COOH-CBD (Rat Micronucleus and Alkaline Comet Assay). The objective of this study was to evaluate the ability of GWP4200370 (also known as 7-COOH-CBD) to induce reverse mutations in five histidine-requiring strains of Salmonella typhimurium in the absence and presence of a rat liver metabolizing system (S-9)."

Request for Supplementary Information adopted on 23.11.2023.

**Epidyolex - Cannabidiol -**
**EMEA/H/C/004675/II/0029, Orphan**

Jazz Pharmaceuticals Ireland Limited,
Rapporteur: Thalia Marie Estrup Blicher,
"Submission of the final report from study GWCP18055. This is a randomized, double-blind, placebo- and positive-controlled, parallel group trial to investigate the effects of multiple therapeutic and supratherapeutic doses of cannabidiol (GWP42003-P) in the fed state on the QT/QTc interval in healthy subjects."


**Evrysdi - Risdiplam -**
**EMEA/H/C/005145/II/0017**

Roche Registration GmbH, Rapporteur: Bruno Sepodes,
"Update of section 5.1 of the SmPC in order to add information on cardiac electrophysiology based on final results from


Request for supplementary information adopted with a specific timetable.
study BP42817 (QTc Study), listed as a category 3 PASS in the RMP. This is a Phase 1, double-blind, placebo and positive controlled crossover study to investigate the effects of risdiplam on QTc interval in healthy subjects.”

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEA/H/C/005145/II/0018</td>
<td>Roche Registration GmbH, Rapporteur: Bruno Sepodes, &quot;Update of section 5.3 of the SmPC in order to update carcinogenicity information based on final results from study 8447237. This is a 104 Week Oral (Gavage) Administration Carcinogenicity Study in the Wistar Rat to investigate the tumorigenic potential of Evrystdi. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.&quot;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEA/H/C/004829/II/0017</td>
<td>Shionogi B.V., Rapporteur: Filip Josephson, &quot;Update of sections 4.5 and 5.2 of the SmPC in order to update drug-drug interaction information with CYP3A4 based on final results from study 2136R2118; this is a Phase 1, open-label, 1-sequence crossover, drug-drug interaction study to assess the effect of repeated doses of cefiderocol on the pharmacokinetics of midazolam in healthy adult participants.”</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEA/H/C/005035/II/0006, Orphan</td>
<td>Amryt Pharmaceuticals DAC, Rapporteur: Kristina Dunder, &quot;Update of sections 4.8 and 5.1 of the SmPC in order to update clinical information based on final results from study EASE (BEB-13); this is a double-blind, randomised, placebo (vehicle) controlled trial to evaluate efficacy and safety of birch bark extract on top of standard of care in children from birth to less than 18 years of age (and adults) with epidermolysis bullosa. In addition, the MAH took the opportunity to introduce minor changes to the PI.”</td>
</tr>
</tbody>
</table>

|---------------------|-----------------------------------------------------|
**EMEA/H/C/005026/II/0017, Orphan**
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol, "Update of sections 4.4 and 4.5 of the SmPC in order to update drug-drug interaction information with dual inhibitors of CYP3A4 and CYP2C19, based on final results from study FEDR-CP-004; this is a phase 1, open-label study to evaluate the effect of a dual CYP2C19 and CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fedratinib in healthy adult subjects.”

**Kesimpta - Ofatumumab - EMEA/H/C/005410/II/0013/G**
Novartis Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, "A grouped application consisting of:
Type II (C.I.4): Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on injection-related reactions and to add 'Hypersensitivity reactions' to the list of adverse drug reactions (ADRs) with frequency not known. The Package Leaflet is updated accordingly.
Type IB (C.I.z): Addition of a statement in the pre-filled syringes (PFS) instructions for use when PFS has been dropped on a hard surface.
Type IA (A.6): To change the ATC Code of ofatumumab from L04AA52 to L04AG12.
In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

**Kyprolis - Carfilzomib - EMEA/H/C/003790/II/0058, Orphan**
Amgen Europe B.V., Rapporteur: Carolina Prieto Fernandez, "Submission of the final report from study 20160275 (CANDOR). This is a randomized, open-label, Phase 3 study comparing carfilzomib, dexamethasone, and daratumumab to carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.”

**LIVTENCITY - Maribavir - EMEA/H/C/005787/II/0008, Orphan**
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Janet Koenig,
Request for supplementary information adopted with a specific timetable.
“Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the updated Population PK analysis data. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

**Lokelma - Sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0033**
AstraZeneca AB, Rapporteur: Larisa Gorobets, "Update of section 4.8 of the SmPC to include information on constipation to the summary of safety profile and to add constipation to the list of adverse drug reactions (ADRs) with frequency Common based on literature review and MAH safety database. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes to the PI.”
Request for Supplementary Information adopted on 07.09.2023.

**Lupkynis - Voclosporin - EMEA/H/C/005256/II/0010**
Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Kristina Dunder, "Submission of the final study report from AUR-VCS-2016-02 (AURORA 2) Kidney Biopsy Substudy, listed as a category 3 study in the RMP. The AURORA 2 extension trial included an optional biopsy substudy which was designed to assess renal histology from tissue samples taken prior to and after approximately 18 months of randomized treatment with voclosporin or placebo.”

**Lydisilka - Drospirenone / Estetrol - EMEA/H/C/005382/II/0021**
Estetra SRL, Duplicate, Duplicate of Drovelis, Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding hepatic impairment based on final results from study MIT-Do001-C102; this is a Phase 1, open-label, parallel group, single-dose study to evaluate the pharmacokinetics and safety of estetrol (E4) in subjects with varying degrees of hepatic function.”
**Maviret - Glecaprevir / Pibrentasvir -**  
**EMEA/H/C/004430/II/0056**  
AbbVie Deutschland GmbH & Co. KG,  
Rapporteur: Jean-Michel Race, "Update of section 5.1 of the SmPC in order to add a statement regarding concordance of SVR4 and SVR12, based on post-hoc analysis of the data from the Phase 2 and 3 clinical trials.”  
Request for Supplementary Information adopted on 23.11.2023.

**Mayzent - Siponimod -**  
**EMEA/H/C/004712/II/0023**  
Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.1 of the SmPC in order to present data on the effect of siponimod on delaying the progression to EDSS ≥7 (time-to-wheelchair) based on post-hoc analysis of study CBAF312A2304 (EXPAND).”  

**Mektovi - Binimetinib -**  
**EMEA/H/C/004579/II/0027**  
Pierre Fabre Medicament, Rapporteur: Janet Koenig, "Submission of the final report from study ARRAY 818-103 on Arms 1 and 3. This is a Phase 1, 3-arm, open-label DDI study in patients with BRAF V600-mutant unresectable or metastatic melanoma or other BRAF V600-E and/or K-mutant advanced solid tumours, to assess drug drug interactions between encorafenib + binimetinib combination and midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), omeprazole (CYP2C19 substrate), losartan (CYP2C9 substrate), dextromethorphan (CYP2D6 substrate) and modafinil (moderate CYP3A4 inducer).”  

**Nexviadyme - Avalglucosidase alfa -**  
**EMEA/H/C/005501/II/0008**  
Sanofi B.V., Rapporteur: Christian Gartner, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the list of adverse drug reactions (ADRs) and to update the safety and efficacy information, based on interim results from the open-label extension period of study EFC14028 as well as pooled safety and
immunogenicity data. EFC14028 is a phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of avalglucosidase alfa and alglucosidase alfa in treatment naïve patients with late-onset Pompe disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Request for Supplementary Information adopted on 14.09.2023, 08.06.2023.

Nexviadyme - Avalglucosidase alfa - EMEA/H/C/005501/II/0012
Sanofi B.V., Rapporteur: Christian Gartner, "Submission of the final report from study LTS13769 listed as a category 3 study in the RMP. This is an interventional, open-label, multicenter, multinational extension study to evaluate long-term safety and pharmacokinetics of repeated biweekly infusions of avalglucosidase alfa in patients with Pompe disease."

Request for Supplementary Information adopted on 31.08.2023.

Paxlovid - Nirmatrelvir / Ritonavir - EMEA/H/C/005973/II/0049/G
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.4 and 4.8 of the SmPC in order to clarify that toxic epidermal necrolysis has been reported with Paxlovid and to add toxic epidermal necrolysis to the list of adverse drug reactions (ADRs) with frequency Rare based on the cumulative review of MAH safety database and literature.
- Update of sections 4.4 and 4.8 of the SmPC in order to clarify that Stevens-Johnson syndrome has been reported with Paxlovid and to add Stevens-Johnson syndrome to the list of adverse drug reactions (ADRs) with frequency Rare, based on the cumulative review of MAH safety database and literature.

The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 09.11.2023.
RAYVOW - Lasmiditan -
EMEA/H/C/005332/II/0004
Eli Lilly Nederland B.V., Rapporteur: Janet Koenig, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with dabigatran and rosuvastatin based on the results from study LAIO, An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers. The aim of study LAIO was to investigate the effect of lasmiditan on the pharmacokinetic profiles of dabigatran (a P-glycoprotein substrate) and rosuvastatin (breast cancer resistance protein substrate) in healthy volunteers. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Request for Supplementary Information adopted on 09.11.2023.

RINVOQ - Upadacitinib -
EMEA/H/C/004760/II/0045
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Submission of the final report from study M15-555, listed as a category 3 study in the RMP. This is phase 3, randomized, double-blind study comparing upadacitinib (ABT-494) monotherapy to methotrexate (MTX) in subjects with moderately to severely active rheumatoid arthritis with inadequate response to MTX.”

Scemblix - Asciminib -
EMEA/H/C/005605/II/0008, Orphan
Novartis Europharm Limited, Rapporteur: Janet Koenig, ”Update of sections 4.5 and 5.2 of the SmPC in order to add interaction information between asciminib and OATP1B and BCRP substrates, based on results from three PBPK simulation reports: DMPK-R2001088, DMPK-R2270328 and DMPK-R2300226. The Package Leaflet is updated accordingly.”

Skilarence - Dimethyl fumarate -
EMEA/H/C/002157/II/0034
Almirall S.A, Rapporteur: Janet Koenig, ”Update
of section 5.1 of the SmPC in order to update long term efficacy and safety information based on final results from study M-41008-41 (Dimeskin 1); this is a phase IV non-randomised, non-interventional, open label study in adult patients with moderate to severe chronic plaque psoriasis to further assess long-term (12 months) efficacy and safety of Skilarence in routine daily practice in Spain."

**Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0114/G**

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Grouped application consisting of:

C.I.4 (Type II): Update of sections 4.4, 4.8 and 5.1 of the SmPC to update the safety information regarding the administration of Spikevax to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, based on updated clinical literature and internal data; the Package Leaflet is updated accordingly.

C.I.2 (Type IB): To update section 6.6 of the SmPC in order to clarify the handling instructions for the pre-filled syringes; the Package Leaflet is updated accordingly."

**Translarna - Ataluren - EMEA/H/C/002720/II/0074, Orphan**

PTC Therapeutics International Limited, Rapporteur: Peter Mol, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to change posology recommendations in paediatric population, to update the summary of safety profile and to update efficacy, safety and pharmacokinetic information on paediatric population based on the final results from study PTC124-GD-048-DMD "A Phase 2, multiple-dose, open-label study evaluating the safety and PK of ataluren in patients with nmDMD aged ≥6 months to <2 years old" (MEA-018). The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes to the PI."

**Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type**

**B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0126**

MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of sections 4.2 and 5.1 of the SmPC in order to add information on interchangeable use of Vaxelis with other hexavalent vaccines based on final results from Study V419-016. In addition, the MAH took this opportunity to introduce minor editorial changes."


Request for Supplementary Information adopted on 31.08.2023.

**Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0128**

MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 4.5 in order to add drug-drug interaction information with meningococcal B conjugate vaccine based on final results from study OVG 2018/05 - Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy; this is an open-label, non-inferiority, randomized clinical trial that compared the immune response and assessed the safety of Vaxelis and control vaccine (Infanrix hexa) when co-administered with 4 component meningococcal B vaccine (4CMenB) along with other routine infant vaccines. The Package Leaflet is updated accordingly."


Request for Supplementary Information adopted on 07.09.2023.

**Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0134**

MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 4.8 of the SmPC in order to add Extensive swelling of vaccinated limb to the list of adverse drug reactions (ADRs) with frequency rare and to update its description based on the cumulative review of clinical studies, literature and safety database."

The Package Leaflet is updated accordingly.”

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -**

EMEA/H/C/005675/II/0095

AstraZeneca AB, Rapporteur: Sol Ruiz, “Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update clinical information, following a critical evaluation of the benefit-risk profile of Vaxzevria against currently circulating variants of concern based on available data and structured benefit risk assessment.”

See 9.1

**VidPrevtyn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant -**

EMEA/H/C/005754/II/0007/G

Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus, “A grouped application consisting of: Type II (C.I.4): Update of section 4.8 of the SmPC in order to include additional safety data based on safety update reports from studies VAT00008 booster extension and VAT00002 Cohort 2, in order to fulfill REC 20. Type IA (A.6): To change the ATC Code of the COVID-19 protein subunit vaccine from J07BX03 to J07BN04.”

**Vokanamet - Canagliflozin / Metformin -**

EMEA/H/C/002656/II/0072

Janssen-Cilag International N.V., Rapporteur: Martina Weise, “Update of section 4.6 of the SmPC in order to update information on pregnancy based on literature and post-marketing data.”

**Xultophy - Insulin degludec / Liraglutide -**

EMEA/H/C/002647/II/0050

Novo Nordisk A/S, Rapporteur: Kristina Dunder, “Update of section 4.8 of the SmPC in order to add Dizziness and Delayed gastric emptying to the list of adverse drug reactions (ADRs) with frequency common and unknown, respectively, based on the cumulative review of clinical studies data, post-marketing data, class labels and biological plausibility. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes to the PI.”


**Yselty - Linzagolix choline -**

EMEA/H/C/005442/II/0010
Theramex Ireland Limited, Rapporteur: Finbarr Leacy, “Submission of the final report from study PRIMROSE 3 (20-OBE2109-007), listed as a category 3 study in the RMP. This is a long-term follow-up study to assess bone mineral density in subjects with uterine fibroids completing the Phase 3 studies of linzagolix, PRIMROSE 1 or PRIMROSE 2.”

Zejula - Niraparib -
EMEA/H/C/004249/II/0044, Orphan
GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, "Submission of the modelling report with the results from the population pharmacokinetic and exposure-response modelling exercises (REC 7)."
Request for Supplementary Information adopted on 07.09.2023.

Zinforo - Ceftaroline fosamil -
EMEA/H/C/002252/II/0063
Pfizer Ireland Pharmaceuticals, Rapporteur: Alar Irs, "Update of section 4.8 of the SmPC in order to add ‘Kounis Syndrome’ to the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.”

ZTALMY - Ganaxolone -
EMEA/H/C/005825/II/0002, Orphan
Marinus Pharmaceuticals Emerald Limited, Rapporteur: Peter Mol, "Submission of the final report from study 1042-HME-1001 listed as post-authorisation measure (PAM) recommendation. This is an interventional Phase 1 Single Dose, Open-Label Crossover Comparative Bioavailability Study of Two Oral Formulations of Ganaxolone. The primary objective of this study was to evaluate and compare the pharmacokinetics of a new ganaxolone formulation with ganaxolone oral suspension after a single oral dose administration under fed conditions.”

WS2467
Adrovance -
EMEA/H/C/000759/WS2467/0051
FOSAVANCE -
Organon N.V., Lead Rapporteur: Christian Gartner, "Update of section 4.4 of the SmPC in order to include information on the risk of 'atypical fractures of other bones' (than the femur), and update of section 4.8 to add 'atypical fractures of other bones' as a new ADR with frequency 'not known' and to include further information about the risk of 'atypical subtrochanteric and diaphyseal femoral fractures', based on post-marketing case reports and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes and to bring the product information in line with the latest QRD template and to update the list of local representatives in the Package Leaflet."
Request for Supplementary Information adopted on 15.06.2023.

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2, 4.6 and 4.8 of the SmPC in order to add 'Dysphonia' and 'Oropharyngeal pain' to the list of adverse drug reactions (ADRs) with frequency rare, and to update the wording regarding the administration instructions and for pregnancy and breastfeeding. The Package Leaflet and Labelling are also updated. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Sanofi Winthrop Industrie, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of..."
section 5.3 of the SmPC in order to update
information on hydrochlorothiazide
monocomponent based on literature review.”
Request for Supplementary Information adopted
on 23.11.2023.

WS2543
Imfinzi-EMEA/H/C/004771/WS2543/0062
IMJUDO-
EMEA/H/C/006016/WS2543/0003
AstraZeneca AB, Lead Rapporteur: Aaron Sosa Mejia, “Update of sections 4.2, 4.8, 5.1 and 5.2
of the SmPC in order to include paediatric
information based on final results from study
D419EC00001 “Phase I/II, Open-Label,
Multicenter Study to Evaluate the Safety,
Tolerability, and Preliminary Efficacy of
Durvalumab Monotherapy or Durvalumab in
Combination with Tremelimumab in Pediatric
Patients with Advanced Solid Tumors and
Hematological Malignancies”. In addition, the
MAH took this opportunity to introduce editorial
changes.”
Request for Supplementary Information adopted
on 09.11.2023.

WS2573/G
Kinzalkomb-
EMEA/H/C/000415/WS2573/0122/G
MicardisPlus-
EMEA/H/C/000413/WS2573/0129/G
PritorPlus-
EMEA/H/C/000414/WS2573/0132/G
Boehringer Ingelheim International GmbH, Lead
Rapporteur: Paolo Gasparini, “Grouped
application consisting of:
C.I.4 (Type II): Update of section 4.8 of the
SmPC in accordance with the “Guideline on fixed
combination medicinal products, Doc. Ref.
CPMP/EWP/240/95 Rev. 1”. The Package Leaflet
is updated accordingly. In addition, the MAH
took the opportunity to implement editorial
changes to the SmPC, Labelling and Annex II of
the PI, as well as, to update the list of local
representatives in the Package Leaflet.
Furthermore, the MAH took the opportunity to
bring the PI in line with the latest QRD template
version 10.3.
C.I.4 (Type II): Update of sections 4.2, 4.3, 4.4,
4.5 and 5.2 of the SmPC in order to align with
reference labels for both active substances. The
Package Leaflet is updated accordingly.

C.I.z (type IB unforeseen): Update of section 4.7 of the SmPC to replace the term "drowsiness" by "syncope or vertigo" to align it with adverse reactions table in section 4.8 of the SmPC. The Package Leaflet is updated accordingly.

C.I.3.a (type IAIN): Update of section 5.3 of the SmPC based on the EMA request dated 31 Jan 2023 for the HCTZ containing medicinal products to remove the sentence '...the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms’ in order to address an inconsistency in the PI.”

B.5.3. CHMP-PRAC assessed procedures

**BESPONSA - Inotuzumab ozogamicin - EMEA/H/C/004119/II/0026, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer, "Update of sections 4.2, 4.6, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies ITCC-059 (WI203581) and INO-Ped-ALL-1 (WI235086). Study WI203581 is a Phase 1/2, multicenter, European, multi-cohort, open-label study in pediatric patients (≥1 and <18 years of age) with R/R CD22-positive Acute Lymphoblastic Leukemia (ALL); and study WI235086 is an open-label, multi-center Phase 1 study to assess safety and tolerability of InO in Japanese pediatric patients with R/R CD22-positive ALL. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted.”


**GAVRETO - Pralsetinib - EMEA/H/C/005413/II/0017**

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2 and 5.2 of the SmPC in order to include information regarding moderate and severe hepatic impairment based on final results from study GP43163 listed as a category 3 study in the RMP; this is a Phase I, open-label, single-dose study to evaluate the..."
pharmacokinetics and safety of pralsetinib in subjects with moderate or severe hepatic impairment compared to healthy subjects.
The RMP version 1.8 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the marketing authorisation renewal date in Annex I.”

Isturisa - Osilodrostat -
EMEA/H/C/004821/II/0017/G, Orphan

Recordati Rare Diseases, Rapporteur: Kristina Dunder, PRAC Rapporteur: Maria del Pilar Rayon, “Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study LINC4 (study CLCI699C2302 - A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s disease).
- Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study LINC3 (study CLCI699C2301 - A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing’s disease).

The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce some minor editorial changes to the PI.”

Kaftrio - Ivacaftor / Tezacaftor / Elexacaftor - EMEA/H/C/005269/II/0039, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber, "Update of sections 4.8 and 5.1 of the SmPC in order to update information based on final results from study VX17-445-105 (study 105); this is a phase 3, open-label, extension study evaluating the long-term safety and

efficacy of ELX/TEZ/IVA treatment in cystic fibrosis (CF) subjects 12 years of age and older, homozygous, or heterozygous for the F508del-CFTR mutation who participated in study VX17-445-102 (study 102) or study VX17-445-103 (study 103). The RMP version 7.2 has also been submitted.”

Request for Supplementary Information adopted on 31.08.2023.

**LUMYKRAS - Sotorasib -**
**EMEA/H/C/005522/II/0010/G**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen, “Update of sections 4.2, 4.4, 4.8, 5.2 and 5.3 of the SmPC in order to change the recommended dose and to update safety and efficacy information based on results from study 20190009 (CodeBreaK 200) listed as a specific obligation in the Annex II, in order to fulfil SOB/001; and results from study 20170543 (CodeBreak 100) Phase 2 Part B.

Study 20190009 is a Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C; while study 20170543 is a Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update Annex II of the SmPC.”

Request for Supplementary Information adopted on 25.05.2023.

See 9.1

**Mavenclad - Cladribine -**
**EMEA/H/C/004230/II/0027**

Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of sections 4.5 and 4.6 of the SmPC in order to add information regarding the use of mavenclad with oral contraceptives

based on the final study results from the drug-drug interaction study (MS 700568-0031). This is a randomized, double-blind, 2-period, 2-sequence, crossover Phase I study with a 1-month run-in period to examine the effect of cladribine tablets on the pharmacokinetics of a monophasic oral contraceptive containing ethinyl estradiol and levonorgestrel (microgynon) in pre-menopausal women with Relapsing Multiple Sclerosis (RMS). The Annex II and Package Leaflet are updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to sections 4.2 and 4.4 of the SmPC.”

Request for Supplementary Information adopted on 31.08.2023.

**Piqray - Alpelisib**

**EMEA/H/C/004804/II/0022/G**

Novartis Europharm Limited, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst, “Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update information on prophylactic use of metformin for hyperglycaemia based on the results from study CBYL719CES01T (METALLICA). METALLICA is a Phase II study aimed to evaluate the effect of prophylactic use of metformin for hyperglycaemia in HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer patients treated with alpelisib plus endocrine therapy.
- Update of section 4.8 of the SmPC in order to add “uveitis” to the list of adverse drug reactions (ADRs) with frequency “Not known” based on a cumulative review of the MAH safety database and literature.

The Package Leaflet and Annex II are updated accordingly. The RMP version 7.0 has also been submitted.”

Request for Supplementary Information adopted with a specific timetable.

**Tegsedi - Inotersen**

**EMEA/H/C/004782/II/0038, Orphan**

Martina Weise, PRAC Rapporteur: Rhea Fitzgerald, "Update of sections 4.4 and 4.8 of the SmPC in order to modify the warning on liver monitoring and drug-induced liver injury and to add 'drug-induced liver injury' to the list of adverse drug reactions (ADRs) with frequency not known, following the request in the Assessment Report for PAM procedure EMEA/H/C/004782/LEG/008. The Annex II and Package Leaflet are updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor updates to the PI."

**Tysabri - Natalizumab -**
**EMEA/H/C/000603/II/0136**
Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post-marketing and clinical study data. The Package Leaflet and Annex IID are updated accordingly. The RMP version 29.1 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes."

**VPRIV - Velaglucerase alfa -**
**EMEA/H/C/001249/II/0063**
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Update of section 4.2 of the SmPC in order to add information to support at-home self-administration of VPRIV by a trained patient and/or a caregiver based on post-marketing data and literature. The Package Leaflet and Annex IID are updated accordingly. The updated RMP version 13.0 has also been submitted."
## B.5.4. PRAC assessed procedures

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HEPLISAV B - Hepatitis B surface antigen (rDNA) - EMEA/H/C/005063/II/0031</strong></td>
<td>Dynavax GmbH, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, &quot;Update of section 4.6 of the SmPC in order to update information on pregnancy based on final results from study DV2-HBV-28 - Post-marketing observational surveillance study to evaluate pregnancy outcomes among women who receive HEPLISAV-B or Engerix-B; HBV-28 was conducted using the same patient population as two observational post-marketing surveillance studies designed to evaluate the incidence of AMI (HBV-25) or new-onset immunemediated diseases, herpes zoster, and anaphylaxis (HBV-26) in recipients of HEPLISAV-B compared with recipients of Engerix-B. The primary objective of this study was to describe and compare pregnancy outcomes in recipients of HEPLISAV-B and recipients of Engerix-B. The Package Leaflet is updated accordingly. The RMP version 1.4 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3.” Request for Supplementary Information adopted on 30.11.2023.</td>
</tr>
</tbody>
</table>
RMP. This is a real-world evidence study to evaluate effectiveness of two drug regimen, antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor. The RMP version 6.1 has also been submitted in order to remove the important identified risk of "drug resistance".


---

**PRAC Led**

**Lenvima - Lenvatinib - EMEA/H/C/003727/II/0053**

Eisai GmbH, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder,

"Submission of interim results from study E7080-M000-508 (STELLAR), listed as a category 3 PASS in the RMP. This is a non-interventional multicentre, observational, phase 4 study to evaluate the safety and tolerability of lenvatinib in patients with advanced or unresectable HCC. Update of section 4.8 of the SmPC to include 'gastrointestinal perforation' as an adverse drug reaction with frequency 'common'. The package leaflet has been updated accordingly. RMP version 15.2 has also been submitted."


---

**PRAC Led**

**MabThera - Rituximab - EMEA/H/C/000165/II/0199**

Roche Registration GmbH, PRAC Rapporteur: Karin Erneholm, PRAC-CHMP liaison: Aaron Sosa Mejia, 

"Submission of the final report for study BE29950 (RIVAS), listed as a category 3 study in the RMP. This is a prospective, single center, secondary data use, long-term surveillance, non-interventional PASS with the objective to better characterise the risk profile of MabThera by collecting long-term safety data in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have been treated with rituximab (MabThera) or other available non-rituximab therapies. The RMP version 24.0 has also been submitted."


---

**PRAC Led**

**Nimenrix - Meningococcal group A, C, W135 and Y conjugate vaccine -**

EMEA/H/C/002226/II/0127
Pfizer Europe MA EEIG, PRAC Rapporteur: David Olsen, PRAC-CHMP liaison: Ingrid Wang,
"Submission of an updated RMP version 9.0 in order to remove the important potential risks 'Change in meningococcal epidemiology/serogroup replacement' and 'Lack of Efficacy' from the list of the safety concerns, to remove 'Long-term persistence of the vaccine response and need for a booster dose' as missing information and to remove 'Use during pregnancy' from the list of safety concerns."

PRAC Led
Nivestim - Filgrastim -
EMEA/H/C/001142/II/0074/G
Pfizer Europe MA EEIG, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Outi Mäki-Ikola,
"Grouped application consisting of:
C.I.13: Submission of the final report from non-interventional PASS study ZOB-NIV-1513/C1121008 listed as a category 3 study in the RMP. This is a multinational, multi-centre, prospective, non-interventional, post-authorisation safety study in Healthy Donors (HDs) exposed to nivestim (biosimilar filgrastim) for Haematopoietic Stem Cell (HSC) Mobilisation (NEST). The RMP version 12 has also been submitted.
C.I.11 for RMP: Submission of an updated RMP version 12.0 in order to align it with the reference product, Neupogen, RMP v. 6.3 dated June 2022."

PRAC Led
Olumiant - Baricitinib -
EMEA/H/C/004085/II/0043
Eli Lilly Nederland B.V., PRAC Rapporteur: Adam Przybyłkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of an updated RMP version 22.1, dated 9 June 2023 in order to remove existing additional pharmacovigilance activities (category 3 studies): Study I4V-MC-JAJA (JAJA) and Study I4V-MC-JAJD (JAJD). The RMP version 22.2, dated 26 September 2023, is acceptable."
Request for Supplementary Information adopted

on 31.08.2023.

PRAC Led
Remicade - Infliximab -
EMEA/H/C/000240/II/0241
Janssen Biologics B.V., PRAC Rapporteur: Mari
Thorn, PRAC-CHMP liaison: Kristina Dunder,
"Submission of the final report for the PSOLAR
(C0168Z03) registry "A Multicenter, Open
Registry of Patients with Psoriasis Who Are
Candidates for Systemic Therapy Including
Biologics: PSOLAR", listed as a category 3 study
in the RMP (MEA114). This is an international,
multicenter, prospective observational registry
for monitoring the long-term safety experience
and clinical status of patients ≥18 years of age
who are eligible to receive or are actively
receiving any systemic therapies for psoriasis,
including those currently receiving or planning
to receive infliximab. The RMP version 21.1 has
also been submitted."
Request for Supplementary Information adopted
on 06.07.2023.

Positive Opinion adopted by consensus on

PRAC Led
Revatio - Sildenafil -
EMEA/H/C/000638/II/0107
Upjohn EESV, PRAC Rapporteur: Menno van der
Elst, PRAC-CHMP liaison: Patrick Vrijlandt,
"Submission of an updated RMP version 8.0 in
order to remove “Long-term Mortality” as
missing information based on the completion of
study A1481324 - A multinational, multicentre
study to assess the effects of oral sildenafil on
mortality in adults with pulmonary arterial
hypertension (PAH). In addition, the MAH took
the opportunity to reflect the completion of the
studies A1481324 and A1481319."

Positive Opinion adopted by consensus on

PRAC Led
Simponi - Golimumab -
EMEA/H/C/000992/II/0117/G
Janssen Biologics B.V., Rapporteur: Kristina
Dunder, PRAC Rapporteur: Mari Thorn, PRAC-
CHMP liaison: Kristina Dunder, "Grouped
application consisting of:
C.I.13: Submission of the final report from
study UC Nordic (MK-8259-013) listed as a
category 3 study in the RMP. This is a Non-
interventional Observational Longitudinal Post

Positive Opinion adopted by consensus on
Authorization Safety Study (PASS) of SIMPONI in Treatment of Ulcerative Colitis using Nordic National Health Registries.
C.I.13: Submission of the final report from study ENEIDA (MK-8259-042) listed as a category 3 study in the RMP. This is a Post-Authorization Safety Study (PASS) of Golimumab in UC Using the Spanish ENEIDA Registry.
The RMP version 27.1 has also been submitted.”

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Vedrop - Tocofersolan</th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Vedrop - Tocofersolan</th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vedrop - Tocofersolan - EMEA/H/C/000920/II/0047</td>
<td>Recordati Rare Diseases, PRAC Rapporteur: Melinda Palfi, PRAC-CHMP liaison: Beata Maria Jakline Ullrich, “Submission of an updated RMP version 10.1 in order to remove all important potential risks and missing information from the list of safety concerns, to align with the new RMP format according to Good Pharmacovigilance Practices Module V Revision 2 and to remove one closed post-authorisation safety study of category 2 (Recordati Rare Diseases's Vedrop registry) from the pharmacovigilance plan.” Request for Supplementary Information adopted on 30.11.2023.</td>
<td></td>
</tr>
</tbody>
</table>

|----------|-----------------------|---------------------------------------------------------------|
Minimisation Measures and List of Safety Concerns removing “Nephrotic syndrome”, “Cardiac failure and ejection fraction decreased”, “Posterior reversible encephalopathy syndrome”, “Thrombotic microangiopathy” and “Osteonecrosis of jaw” of the important identified risks, “Reproductive and developmental toxicity” as an important potential risk and “Safety in patients with severe hepatic impairment” of the missing information, following the assessment of PSUSA/00010019/202108.”


PRAC Led
WS2569
Corlentor-
EMEA/H/C/000598/WS2569/0059
Ivabradine Anpharm-
EMEA/H/C/004187/WS2569/0019
Procoralan-
EMEA/H/C/000597/WS2569/0058
Les Laboratoires Servier, Lead PRAC
Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Patrick Vrijlandt, “C.I.11.z - To update the RMP to delete the obsolete products (Ivabradine Egis and Ivabradine Proterapia) that are still mentioned in the RMP.”

PRAC Led
WS2571
Glyxambi-
EMEA/H/C/003833/WS2571/0055
Jardiance-
EMEA/H/C/002677/WS2571/0082
Synjardy-
EMEA/H/C/003770/WS2571/0076
Boehringer Ingelheim International GmbH, Lead PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Carolina Prieto Fernandez, “Submission of the final report from study 1245-0201. This is an observational post-authorisation safety study (PASS) to assess the risk of acute pancreatitis in type 2 diabetes mellitus (T2DM) patients newly initiating empagliflozin compared to other oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2i)-containing glucose lowering drugs. The RMP versions 22.0, 15.0 and 10.0 have also been submitted for Jardiance, Synjardy and Glyxambi, respectively.”

Request for supplementary information adopted with a specific timetable.

### B.5.5. CHMP-CAT assessed procedures

**Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G, ATMP**
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini
Request for Supplementary Information adopted on 15.06.2023.

**Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0026/G, ATMP**
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini
Request for Supplementary Information adopted on 08.09.2023.

**Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0032, ATMP**
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini

**Hemgenix - Etranacogene dezaparvovec - EMEA/H/C/004827/II/0009/G, Orphan, ATMP**
CSL Behring GmbH, Rapporteur: Silke Dorner, CHMP Coordinator: Daniela Philadelphia

**Libmeldy - Atidarsagene autotemcel - EMEA/H/C/005321/II/0021, Orphan, ATMP**
Orchard Therapeutics (Netherlands) B.V., Rapporteur: Emmely de Vries, CHMP Coordinator: Peter Mol

**Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells**
transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0039, Orphan, ATMP
Fondazione Telethon ETS, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro

**Yescarta - Axicabtagene ciloleucel - EMEA/H/C/004480/II/0065, Orphan, ATMP**
Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to add Infusion Related Reactions to the list of adverse drug reactions (ADRs) with frequency Common, based on a cumulative review of the MAH safety database, clinical trials and postmarketing data. The Package Leaflet is updated accordingly.”

**B.5.6. CHMP-PRAC-CAT assessed procedures**

**B.5.7. PRAC assessed ATMP procedures**

**B.5.8. Unclassified procedures and worksharing procedures of type I variations**

**WS2408**
Riarify-EMEA/H/C/004836/WS2408/0027
Trydonis-
EMEA/H/C/004702/WS2408/0030

**WS2528/G**
Eucreas-
EMEA/H/C/000807/WS2528/0101/G
Icandra-
EMEA/H/C/001050/WS2528/0106/G
Zomarist-
EMEA/H/C/001049/WS2528/0103/G
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "C.1.z - To provide the Environmental Risk Assessment (ERA) report for vildagliptin to add data from OECD TG308 and OECD TG218 studies.
C.I.z - To provide the Environmental Risk Assessment (ERA) report for metformin to add FOCUS_DEGKINv2 SFO calculated DT50 values.”


<table>
<thead>
<tr>
<th><strong>WS2540</strong></th>
<th>Biktarvy-EMEA/H/C/004449/WS2540/0057</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Descovy-EMEA/H/C/004094/WS2540/0064</td>
</tr>
<tr>
<td></td>
<td>Genvoya-EMEA/H/C/004042/WS2540/0088</td>
</tr>
<tr>
<td></td>
<td>Odefsey-EMEA/H/C/004156/WS2540/0062</td>
</tr>
<tr>
<td></td>
<td>Vemlidy-EMEA/H/C/004169/WS2540/0044</td>
</tr>
</tbody>
</table>

Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes

<table>
<thead>
<tr>
<th><strong>WS2561/G</strong></th>
<th>Olanzapine Glenmark-EMEA/H/C/001085/WS2561/0041/G</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Olanzapine Glenmark Europe-EMEA/H/C/001086/WS2561/0038/G</td>
</tr>
<tr>
<td></td>
<td>Olazax-EMEA/H/C/001087/WS2561/0033/G</td>
</tr>
<tr>
<td></td>
<td>Olazax Disperzi-EMEA/H/C/001088/WS2561/0035/G</td>
</tr>
</tbody>
</table>

Glenmark Arzneimittel GmbH, Generic, Generic of Olansek (SRD), Zyprexa, Zyprexa Velotab, Lead Rapporteur: Alexandre Moreau

<table>
<thead>
<tr>
<th><strong>WS2570</strong></th>
<th>Lantus-EMEA/H/C/000284/WS2570/0131</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Suliqua-EMEA/H/C/004243/WS2570/0036</td>
</tr>
<tr>
<td></td>
<td>Toujeo-EMEA/H/C/000309/WS2570/0126</td>
</tr>
</tbody>
</table>

Sanofi-Aventis Deutschland GmbH, Lead Rapporteur: Patrick Vrijlandt
Request for Supplementary Information adopted on 16.11.2023, 05.10.2023.

<table>
<thead>
<tr>
<th><strong>WS2572/G</strong></th>
<th>Herceptin-EMEA/H/C/000278/WS2572/0191/G</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MabThera-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Registration Number</th>
<th>Company Name</th>
<th>Lead Rapporteur</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEA/H/C/000165/WS2572/0200/G</td>
<td>Roche Registration GmbH</td>
<td>Jan Mueller-Berghaus</td>
<td>Positive Opinion adopted by consensus on</td>
</tr>
<tr>
<td>WS2581/G</td>
<td>Fluenz Tetra-AstraZeneca</td>
<td></td>
<td>Positive Opinion adopted by consensus on</td>
</tr>
<tr>
<td>Pandemic influenza vaccine H5N1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2581/G/003963/WS2581/0070/G</td>
<td>AstraZeneca AB, Lead Rapporteur:</td>
<td>Christophe Focke</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2589</td>
<td>Ongentys-Bial - Portela &amp; C³, S.A.</td>
<td>Martina Weise</td>
<td>Positive Opinion adopted by consensus on</td>
</tr>
<tr>
<td>Ontilyv-EMEA/H/C/005782/WS2589/0017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2592/G</td>
<td>Nuwiq-Octapharma AB, Lead Rapporteur:</td>
<td>Jan Mueller-Berghaus</td>
<td>Positive Opinion adopted by consensus on</td>
</tr>
<tr>
<td>Vihuma-EMEA/H/C/004459/WS2592/0038/G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2592/G/002813/WS2592/0056/G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2602/G</td>
<td>Eucreas-Novartis Europharm Limited,</td>
<td>Kristina Dunder</td>
<td>Positive Opinion adopted by consensus on</td>
</tr>
<tr>
<td>Icandra-EMEA/H/C/001050/WS2602/0109/G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zomarist-EMEA/H/C/001049/WS2602/0106/G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2602/G/001050/WS2602/0109/G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS2614</td>
<td>Cegfila-Mundipharma Corporation</td>
<td>Karin Janssen van Doorn</td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/005312/WS2614/0019</td>
<td>(Ireland) Limited, Lead Rapporteur:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelmeg-EMEA/H/C/004700/WS2614/0027</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.5.9. Information on withdrawn type II variation / WS procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremelimumab AstraZeneca -</td>
<td>The MAH withdrew the procedure on</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremelimumab -</td>
<td>29.11.2023.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/004650/II/0002</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the paediatric information based on final results from study D419EC00001; this is a Phase I/II, open-label, multicenter study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumors and haematological malignancies.” Withdrawal request submitted on 29.11.2023.

Zolsketil pegylated liposomal - Doxorubicin - EMEA/H/C/005320/II/0004
Accord Healthcare S.L.U., Rapporteur: Carolina Prieto Fernandez

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

Dimethyl fumarate - EMEA/H/C/006397
for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

Garadacimab - EMEA/H/C/006116, Orphan
CSL Behring GmbH, routine prevention of attacks of hereditary angioedema (HAE)

Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated - EMEA/H/C/005797
prevention of disease caused by chikungunya (CHIKV) virus

Accelerated review

Aflibercept - EMEA/H/C/006056
treatment of age-related macular degeneration (AMD) and visual impairment

Beremagene geperpavec -
EMEA/H/C/006330, Orphan, ATMP
Krystal Biotech Netherlands B.V., treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1)
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0199
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Extension application to add a new presentation of Comirnaty Omicron XBB.1.5, 3 micrograms/dose concentrate for dispersion for injection (yellow caps, 3-doses per vial) for infants and children aged 6 months to 4 years."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

Abilify Maintena - Aripiprazole - EMEA/H/C/002755/X/0045
Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce a new pharmaceutical form associated with two new strengths (720 and 960 mg Prolonged-release suspension for injection). The RMP (version 12.1) is updated in accordance."
List of Questions adopted on 09.11.2023.

In vitro diagnostic medical device - EMEA/H/D/006372
next generation sequencing (NGS) assay for tumor mutation profiling
Request for Supplementary Information adopted on 09.11.2023.

Denosumab - EMEA/H/C/005964
treatment of osteoporosis

In vitro diagnostic medical device - EMEA/H/D/006373
detection of PD-L1 protein
Request for Supplementary Information adopted on 09.11.2023, 12.10.2023.

TEPADINA - Thiotepa - EMEA/H/C/001046/X/0049
ADIENNE S.r.l. S.U., Rapporteur: Alexandre Moreau, "Extension application to add a new
strength (200 mg powder and solvent for solution for infusion).”
List of Questions adopted on 09.11.2023.

Denosumab - EMEA/H/C/006378
prevention of skeletal related events with advanced malignancies

B.6.4. Annual Re-assessments: timetables for adoption

NULIBRY - Fosdenopterin -
EMEA/H/C/005378/S/0006, Orphan
TMC Pharma (EU) Limited, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Martin Huber

NYXTHRACIS - Obiltoxaximab -
EMEA/H/C/005169/S/0013, Orphan
SFL Pharmaceuticals Deutschland GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Liana Martirosyan

Orphacol - Cholic acid -
EMEA/H/C/001250/S/0053
Theravia, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Sofia Trantza

Raxone - Idebenone -
EMEA/H/C/003834/S/0035, Orphan

Vedrop - Tocofersolan -
EMEA/H/C/000920/S/0049
Recordati Rare Diseases, Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Melinda Palfi

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

CARVYKTI - Ciltacabtagene autoleucel -
EMEA/H/C/005095/R/0025, Orphan, ATMP
Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Lacosamide UCB - Lacosamide -
EMEA/H/C/005243/R/0020
B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Hepcludex - Bulevirtide -
EMEA/H/C/004854/II/0031, Orphan
Gilead Sciences Ireland Unlimited Company,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Adam Przybylkowski, "Extension of indication to
include treatment of chronic hepatitis delta virus
(HDV) infection in paediatric patients 3 years of
age and older weighing at least 10 kg with
compensated liver disease for Hepcludex, based
on a modelling and simulation study and an
extrapolation study to evaluate the use of
Bulevirtide for the treatment of chronic hepatitis
D infection in children from 3 to less than 18
years of age. As a consequence, sections 4.1,
4.2, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet has been updated accordingly. Version 4.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI.”

**Pegasys - Peginterferon alfa-2a - EMEA/H/C/000395/II/0119/G**
Pharmaand GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga,
“Grouped application consisting of:
Extension of indication to include treatment of Polycythaemia Vera (PV) and Essential thrombocytopenia (ET) for PEGASYS, based on published data of clinical studies conducted in support of the efficacy and safety of Pegasys for the treatment of ET and PV. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.3.”

**SIRTURO - Bedaquiline - EMEA/H/C/002614/II/0056, Orphan**
Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, “Extension of indications by removal of the restriction for use of SIRTURO (bedaquiline [BDQ]), based on final results from study STREAM Stage 2; this is an multicenter, open-label, parallel-group, randomized, active-controlled study in participants aged 15 years or older with RR/MDR-TB to evaluate an investigational BDQ-containing, all-oral, 40-week regimen of anti-TB drugs (Regimen C) compared to an injectable-containing 40-week control regimen (Regimen B). As a consequence of the data emerging from the submitted study, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. In addition, section E of Annex II has also been updated. The Labelling and Package Leaflet are updated in accordance. Version 10.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.3. As part of the application, the MAH is requesting the switch from a conditional MA to standard MA.”
**Tepkinly - Epcoritamab -**  
**EMEA/H/C/005985/II/0001, Orphan**  
AbbVie Deutschland GmbH & Co. KG,  
Rapporteur: Peter Mol, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Monica Martinez Redondo, "Extension of indication to include treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy for TEPKINLY, based on results from the indolent Non-Hodgkins Lymphoma (iNHL) expansion cohort of study GCT3013-01, the First In Human (FIH) Phase 1/2 study in R/R B-NHL, with key supportive data from the Phase 1b/2 Study GCT3013-04 in Japanese subjects. Study GCT3013-01 is an ongoing global, single-arm, Phase 1/2 study designed to evaluate epcoritamab as monotherapy in R/R B-NHL. As a consequence, sections 1, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.3, 6.4, 6.5 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**WS2551**  
**Kaftrio-EMEA/H/C/005269/WS2551/0043**  
**Kalydeco-EMEA/H/C/002494/WS2551/0121**  
Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Peter Mol, Lead PRAC Rapporteur: Martin Huber, "Extension of the indication for Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) in a combination regimen to include the treatment of patients with cystic fibrosis (CF) aged 2 years and older who do not carry any F508del mutations and have at least one ivacaftor/tezacaftor/elexacaftor-responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene based on study VX21-445-124, study VX21-445-125 and study VX22-CFD-016. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the Kaftrio SmPC are updated; sections 4.1 and 5.1 of the Kalydeco SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took this opportunity to introduce
editorial changes to the PI."

### B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMA/H/C/number/II/number/G</th>
<th>Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adtralza - Tralokinumab -</td>
<td>EMEA/H/C/005255/II/0014/G</td>
<td>LEO Pharma A/S, Jayne Crowe</td>
</tr>
<tr>
<td>Adtralza - Tralokinumab -</td>
<td>EMEA/H/C/005255/II/0015</td>
<td>LEO Pharma A/S, Jayne Crowe</td>
</tr>
<tr>
<td>Artesunate Amivas - Artesunate -</td>
<td>EMEA/H/C/005550/II/0011, Orphan</td>
<td>Amivas Ireland Limited, Jayne Crowe</td>
</tr>
<tr>
<td>ASPAVELI - Pegcetacoplan -</td>
<td>EMEA/H/C/005553/II/0015, Orphan</td>
<td>Swedish Orphan Biovitrum AB (publ), Alexandre Moreau</td>
</tr>
<tr>
<td>Aybintio - Bevacizumab -</td>
<td>EMEA/H/C/005106/II/0019/G</td>
<td>Samsung Bioepis NL B.V., Christian Gartner</td>
</tr>
<tr>
<td>Benepali - Etanercept -</td>
<td>EMEA/H/C/004007/II/0078</td>
<td>Samsung Bioepis NL B.V., Christian Gartner</td>
</tr>
<tr>
<td>Bortezomib SUN - Bortezomib -</td>
<td>EMEA/H/C/004076/II/0022</td>
<td>Sun Pharmaceutical Industries Europe B.V., Margareta Bego</td>
</tr>
<tr>
<td>Briumvi - Ublituximab -</td>
<td>EMEA/H/C/005914/II/0006</td>
<td>Neuraxpharm Pharmaceuticals S.L., Ewa Balkowiec Iskra</td>
</tr>
<tr>
<td>Cablivi - Caplacizumab -</td>
<td>EMEA/H/C/004426/II/0047/G, Orphan</td>
<td>Ablynx NV, Filip Josephson</td>
</tr>
<tr>
<td>Cancidas - Caspofungin -</td>
<td>EMEA/H/C/000379/II/0083/G</td>
<td>Merck Sharp &amp; Dohme B.V.,</td>
</tr>
</tbody>
</table>
Christophe Focke

**Cervarix - Human papillomavirus vaccine**
[types 16, 18] (recombinant, adjuvanted, adsorbed) -
EMEA/H/C/000721/II/0126/G
GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke

**Clopidogrel Viatris - Clopidogrel** -
EMEA/H/C/001189/II/0049/G
Viatris Limited, Generic, Duplicate, Generic of Plavix, Duplicate of Grepid, Rapporteur: Kristina Nadrah

**COMIRNATY - COVID-19 mRNA vaccine**
(nucleoside-modified) -
EMEA/H/C/005735/II/0197/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

**Cosentyx - Secukinumab** -
EMEA/H/C/003729/II/0110
Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola

**Ebixa - Memantine / Memantine hydrochloride** -
EMEA/H/C/000463/II/0101
H. Lundbeck A/S, Duplicate, Duplicate of Axura, Rapporteur: Maria Concepcion Prieto Yerro

**Elfabrio - Pegunigalsidase alfa** -
EMEA/H/C/005618/II/0002
Chiesi Farmaceutici S.p.A., Rapporteur: Alexandre Moreau

**EXPAREL liposomal - Bupivacaine** -
EMEA/H/C/004586/II/0018
Pacira Ireland Limited, Rapporteur: Elita Poplavská

**Flucelvax Tetra - Influenza vaccine**
(surface antigen, inactivated, prepared in cell cultures) -
EMEA/H/C/004814/II/0044
Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

**Foclivia - Pandemic Influenza vaccine**
(surface antigen, inactivated, adjuvanted) -
EMEA/H/C/001208/II/0084/G
Seqirus S.r.l, Rapporteur: Maria Grazia Evandri

**Gliolan - 5-aminolevulinic acid** -
EMEA/H/C/000744/II/0026/G
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Code</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hetliz - Tasimelteon</td>
<td>EMEA/H/C/003870/II/0037, Orphan</td>
<td>Rapp.: Bruno Sepodes</td>
</tr>
<tr>
<td>Ixiaro - Japanese encephalitis vaccine (inactivated, adsorbed)</td>
<td>EMEA/H/C/000963/II/0116</td>
<td>Rapp.: Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>MINJUVI - Tafasitamab</td>
<td>EMEA/H/C/005436/II/0014/G, Orphan</td>
<td>Rapp.: Filip Josephson</td>
</tr>
<tr>
<td>Nimenrix - Meningococcal group A, C, W135 and Y conjugate vaccine</td>
<td>EMEA/H/C/002226/II/0130/G</td>
<td>Rapp.: Ingrid Wang</td>
</tr>
<tr>
<td>Nulojix - Belatacept</td>
<td>EMEA/H/C/002098/II/0090/G</td>
<td>Rapp.: Filip Josephson</td>
</tr>
<tr>
<td>Ontruzant - Trastuzumab</td>
<td>EMEA/H/C/004323/II/0049</td>
<td>Rapp.: Karin Janssen van Doorn</td>
</tr>
<tr>
<td>Ovitrelle - Choriogonadotropin alfa</td>
<td>EMEA/H/C/000320/II/0090</td>
<td>Rapp.: Patrick Vrijlandt</td>
</tr>
<tr>
<td>Pedmarqsi - Sodium thiosulfate</td>
<td>EMEA/H/C/005130/II/0002/G</td>
<td>Rapp.: Elita Poplavska</td>
</tr>
<tr>
<td>Pemetrexed Fresenius Kabi - Pemetrexed</td>
<td>EMEA/H/C/003895/II/0035/G</td>
<td>Rapp.: Eva Skovlund</td>
</tr>
<tr>
<td>Posaconazole Accord - Posaconazole</td>
<td>EMEA/H/C/005005/II/0012/G</td>
<td>Rapp.: Karin Janssen van Doorn</td>
</tr>
<tr>
<td>Medicine</td>
<td>Description</td>
<td>Referee and Company</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>PREVYMIS - Letermovir</td>
<td>EMEA/H/C/004536/II/0036, Orphan</td>
<td>Merck Sharp &amp; Dohme B.V., Rapporteur: Filip Josephson</td>
</tr>
<tr>
<td>Refixia - Nonacog beta pegol</td>
<td>EMEA/H/C/004178/II/0036/G</td>
<td>Novo Nordisk A/S, Rapporteur: Daniela Philadelphy</td>
</tr>
<tr>
<td>Skytrofa - Lonapegsomatropin</td>
<td>EMEA/H/C/005367/II/0024, Orphan</td>
<td>Ascendis Pharma Endocrinology Division A/S, Rapporteur: Patrick Vrijlandt</td>
</tr>
<tr>
<td>Skytrofa - Lonapegsomatropin</td>
<td>EMEA/H/C/005367/II/0025/G, Orphan</td>
<td>Ascendis Pharma Endocrinology Division A/S, Rapporteur: Patrick Vrijlandt</td>
</tr>
<tr>
<td>Somavert - Pegvisomant</td>
<td>EMEA/H/C/000409/II/0108/G</td>
<td>Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race</td>
</tr>
<tr>
<td>Sugammadex Piramal - Sugammadex</td>
<td>EMEA/H/C/006083/II/0001</td>
<td>Piramal Critical Care B.V., Generic, Generic of Bridion, Rapporteur: Hrefna Gudmundsdottir</td>
</tr>
<tr>
<td>Supemtek - Influenza quadrivalent vaccine (rDNA)</td>
<td>EMEA/H/C/005159/II/0013/G</td>
<td>Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Supemtek - Influenza quadrivalent vaccine (rDNA)</td>
<td>EMEA/H/C/005159/II/0015/G</td>
<td>Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Tabrecta - Capmatinib</td>
<td>EMEA/H/C/004845/II/0007/G</td>
<td>Novartis Europharm Limited, Rapporteur: Carolina Prieto Fernandez</td>
</tr>
<tr>
<td>TEPMETKO - Tepotinib</td>
<td>EMEA/H/C/005524/II/0012</td>
<td>Merck Europe B.V., Rapporteur: Filip Josephson</td>
</tr>
<tr>
<td>Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EMEA/H/C/003982/II/0136/G
MCM Vaccine B.V., Rapporteur: Christophe Focke

Yellox - Bromfenac -
EMEA/H/C/001198/II/0036/G
Bausch + Lomb Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher

Zirabez - Bevacizumab -
EMEA/H/C/004697/II/0032
Pfizer Europe MA EEIG, Rapporteur: Eva Skovlund

WS2557/G
Infanrix hexa-
EMEA/H/C/000296/WS2557/0337/G
GlaxoSmithKline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2590
Eucreas-
EMEA/H/C/000807/WS2590/0103
Galvus-EMEA/H/C/000771/WS2590/0081
Icandra-
EMEA/H/C/001050/WS2590/0108
Jalra-EMEA/H/C/001048/WS2590/0084
Xiliarx-EMEA/H/C/001051/WS2590/0082
Zomarist-
EMEA/H/C/001049/WS2590/0105
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder

WS2625
Hukyndra-
EMEA/H/C/005548/WS2625/0020
Libmyris-
EMEA/H/C/005947/WS2625/0009
STADA Arzneimittel AG, Lead Rapporteur: Outi Mäki-Ikola

Mosquirix-
EMEA/H/W/002300/WS2585/0078
Shingrix-
EMEA/H/C/004336/WS2585/0071
GlaxoSmithKline Biologicals SA, Lead Rapporteur: Jan Mueller-Berghaus

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

AREXVY - Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted
with AS01E - EMEA/H/C/006054/II/0004

GlaxoSmithKline Biologicals S.A., Rapporteur: Patrick Vrijlandt, "Update of sections 4.8 and 5.1 of the SmPC in order to include data on persistence of protection over at least 2 RSV seasons following administration of a single dose of Arexvy based on final results from study RSV OA=ADJ-006 (A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above) and RSV OA=ADJ-004 (A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above)."

Benlysta - Belimumab - EMEA/H/C/002015/II/0117

GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, "Update of section 4.4 of the SmPC in order to amend an existing warning and precautions for Progressive multifocal leukoencephalopathy (PML) following the recent review of the wording in the company Core Safety Datasheet."

Benlysta - Belimumab - EMEA/H/C/002015/II/0118

GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to change the frequency of urticaria and rash from uncommon to common and to change the frequency of diarrhoea and nausea from very common to common and to update the Summary of the safety profile based on a cumulative review of clinical trials. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes."

Bimzelx - Bimekizumab - EMEA/H/C/005316/II/0025

UCB Pharma S.A., Rapporteur: Finbarr Leacy, "Update of section 5.1 of the SmPC in order to add long-term efficacy data based on the interim results (week 144 data) from study PS0014 listed as a category 3 study in the RMP"
(MEA/005); this is an ongoing, multicenter, open-label extension (OLE) study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate to severe plaque PSO who completed 1 of the 3 completed feeder studies (PS0008, PS0009, and PS0013).”

**BYANNLI - Paliperidone - EMEA/H/C/005486/II/0005**  

**CAMZYOS - Mavacamten - EMEA/H/C/005457/II/0006**  
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Patrick Vrijlandt, "Update of section 4.9 of the SmPC in order to include information on the management of mavacamten overdose with administration of activated charcoal, based on final results from study CV027043. This is a single-center, open-label, randomized, parallel-group study to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose PK of mavacamten in healthy subjects. In addition, the MAH took the opportunity to introduce minor updates to the PI and to update the list of local representatives in the Package Leaflet.”

**COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0194**  
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, “Submission of the final report from study C4591014 listed as a category 3 study in the RMP. This is a retrospective database study to evaluate the effectiveness of COVID-19 BNT162b2 vaccine in a real-world setting.”

**Edarbi - Azilsartan medoxomil - EMEA/H/C/002293/II/0033/G**  
Takeda Pharma A/S, Rapporteur: Patrick Vrijlandt, "Grouped application comprising two type II variations as follows:  
- Update of section 4.8 of the SmPC in order to add rhabdomyolysis to the list of adverse drug reactions (ADRs) with frequency Not known
based on the cumulative review of MAH safety database and literature.
- Update of section 4.8 of the SmPC in order to add arthralgia to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of MAH safety database and literature.
The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI.”

Evrysdi - Risdiplam -
EMEA/H/C/005145/II/0021
Roche Registration GmbH, Rapporteur: Bruno Sepodes, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on primary analysis results from study BN40703 (RAINBOWFISH); this is an open-label, single-arm, multicenter clinical study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of risdiplam in patients aged from birth to 6 weeks (at first dose) who are genetically diagnosed with SMA (SMN1 deletion and any SMN2 copies) but not yet presenting with symptoms. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instructions for Use.”

Gardasil 9 - Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) -
EMEA/H/C/003852/II/0069
Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update long-term effectiveness information based on results from the 4th interim report for study V503-021, listed as a category 3 study in the RMP. This is a registry-based extension of protocol V503-001 in countries with centralised cervical cancer screening infrastructures to evaluate the long-term effectiveness, immunogenicity, and safety of 9vHPV vaccine as administered to 16- to 26-year-old women. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.”

Gazyvaro - Obinutuzumab -
EMEA/H/C/002799/II/0054/G, Orphan
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, "Grouped application comprising two variations as follows:

C.1.4 - Update of section 4.4 of the SmPC in order to amend the cytokine release syndrome (CRS) statement based on the cumulative review of the MAH safety database, clinical trials and literature. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.3.

A.6 - To change the ATC Code of Obinutuzumab from L01XC15 to L01FA03."

Imbruvica - Ibrutinib -
EMEA/H/C/003791/II/0083
Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC following the 24-month extended follow up from primary analysis data from study CLL3011. This is a randomized, open-label, Phase 3 Study of the combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). In addition, the MAH took the opportunity to add a footnote to the dose modifications table for non-cardiac events in section 4.2 to define the grading systems used for the adverse reactions."

Instanyl - Fentanyl -
EMEA/H/C/000959/II/0081
Takeda Pharma A/S, Rapporteur: Alexandre Moreau, "Update of section 4.9 of the SmPC in order to add Toxic Leukoencephalopathy as a symptom overdose based on the cumulative review of safety databases, clinical trial data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI."

Keytruda - Pembrolizumab -
EMEA/H/C/003820/II/0147
Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, "Update of section 5.1 of the SmPC in order to update efficacy information based on
final results from study KEYNOTE-B61; this is a Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC)."

**Kineret - Anakinra -**
**EMEA/H/C/000363/II/0092**
Swedish Orphan Biovitrum AB (publ), Rapporteur: Thalia Marie Estrup Blicher,
"Update of section 4.8 of the SmPC in order to add 'Injection site amyloid deposits' to the list of adverse drug reactions (ADRs) with frequency not known, based on a review of the clinical study and post-marketing data to evaluate a possible causal association between anakinra (Kineret) and amyloidosis. The Package Leaflet is updated accordingly."

**Kisplyx - Lenvatinib -**
**EMEA/H/C/004224/II/0058**
Eisai GmbH, Rapporteur: Karin Janssen van Doorn, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-B61; this is a phase 2, single-arm, open-label clinical trial of pembrolizumab plus lenvatinib in participants with first-line advanced/metastatic non-clear cell Renal Cell Carcinoma (nccRCC). In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

**LIVMARLI - Maralixibat -**
**EMEA/H/C/005857/II/0009, Orphan**
Mirum Pharmaceuticals International B.V., Rapporteur: Martina Weise, "Update of section 5.3 of the SmPC in order to update preclinical safety information based on final results from study MRX-NC-006, listed as a category 3 study in the RMP. This is a 104-week oral gavage carcinogenity study of maralixibat in Sprague Dawley Rats performed to evaluate the toxicity and carcinogenic potential of maralixibat."

**Mavenclad - Cladribine -**
**EMEA/H/C/004230/II/0032**
Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, “Update of section 4.4 of the SmPC in order to update an existing warning on infections. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce an editorial update to
the PI."

**Nexviadyme - Avalglucosidase alfa - EMEA/H/C/005501/II/0015**
Sanofi B.V., Rapporteur: Christian Gartner,
"Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update safety and efficacy information based on final results from study EFC14028 - COMparative Enzyme replacement Trial with neoGAA versus rhGAA (COMET), listed as a category 3 study in the RMP. This is a phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of avalglucosidase alfa (neoGAA, GZ402666) and alglucosidase alfa in treatment naive patients with late onset Pompe disease. In addition, the MAH took this opportunity to update the list of local representatives in the Package Leaflet."

**Olumiant - Baricitinib - EMEA/H/C/004085/II/0046**
Eli Lilly Nederland B.V., Rapporteur: Peter Mol,
"Update of section 5.1 of the SmPC in order to add information on JIA-associated uveitis or chronic anterior antibody positive uveitis based on interim results from study I4VMC-JAHW; this is an open-label, active-controlled, safety, and efficacy study of oral baricitinib in patients from 2 years to less than 18 years old with active juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis."

**Oxlumo - Lumasiran - EMEA/H/C/005040/II/0017, Orphan**
Alnylam Netherlands B.V., Rapporteur: Martina Weise, "Submission of the final report from study ALN-GO1-002 (study 002), listed as a category 3 study in the RMP. This is a phase 2, multicenter, open-label, extension study to evaluate the long-term administration of ALN-GO1 in patients with primary hyperoxaluria type 1."

**OZAWADE - Pitolisant - EMEA/H/C/005117/II/0007**
Bioprojet Pharma, Rapporteur: Peter Mol,
"Submission of the final report from study P21-03. This is an open label, single center, drug-drug interaction study to evaluate the effect of a combination of itraconazole and paroxetine"
treatment on the pitolisant pharmacokinetics at steady-state in eighteen healthy male Caucasian subjects.”

**Paxlovid - Nirmatrelvir / Ritonavir - EMEA/H/C/005973/II/0051/G**
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising of the following variations:
Type II (C.I.4): Update of section 4.2 of the SmPC in order to add clarifying language to the posology section to distinguish between symptom severity and baseline disease severity.
Type II (C.I.4): Update of section 4.4 of the SmPC in order to add information on severe, life-threatening, and fatal drug reactions associated with DDIs.
Type II (C.I.4): Update of section 4.6 of the SmPC in order to clarify that there is limited human data on the use of Paxlovid during pregnancy.
Type II (C.I.4): Update of section 5.1 of the SmPC in order to update information on antiviral activity.”

**PONVORY - Ponesimod - EMEA/H/C/005163/II/0013**
Janssen-Cilag International N.V., Rapporteur: Peter Mol, "Update of section 4.4 of the SmPC to amend an existing warning on PML-IRIS based on the cumulative review of literature. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to introduce editorial changes to the PI and to bring the PI in line with the latest QRD template version 10.3.”

**PONVORY - Ponesimod - EMEA/H/C/005163/II/0014**
Janssen-Cilag International N.V., Rapporteur: Peter Mol, "Update of section 4.5 of the SmPC to amend an existing interaction wording for carbamazepine under the sub-heading "Effect of other medicinal products on ponesimod” based on study 67896153MSC1001. This is a Phase 1, Open-label, Parallel-group Study to Assess the Effect of Steady-state Carbamazepine on the Pharmacokinetics of Ponesimod in Healthy Adult Participants. In addition, the MAH took the opportunity to update the contact details of local representatives in the Package Leaflet.”
Puregon - Follitropin beta -
EMEA/H/C/000086/II/0128
Organon N.V., Rapporteur: Finbarr Leacy,
"Update of section 4.8 of the SmPC in order to
add "anaphylactic reactions" to the list of
adverse drug reactions (ADRs) with frequency
not known, based on post-marketing
surveillance data. The Package Leaflet is
updated accordingly. In addition, the MAH took
the opportunity to introduce minor changes to
the PI and to bring it in line with the latest QRD
template."

QUVIVIQ - Daridorexant -
EMEA/H/C/005634/II/0013/G
Idorsia Pharmaceuticals Deutschland GmbH,
Rapporteur: Alexandre Moreau, "Update of
sections 4.4, 4.5 and 5.1 of the SmPC in order
to reflect the conclusions of studies ID-075-121,
ID-078-122 and ID-078-118, respectively. The
Package Leaflet was updated accordingly. Study
ID-078-121 is a randomized, double-blind,
placebo-controlled, 2-way crossover study to
investigate the effects of daridorexant on
nighttime respiratory function and sleep in
subjects with severe obstructive sleep apnea;
study ID-078-122 is a prospective, open-label,
single-dose Phase 1 study to measure
daridorexant in breast milk of healthy lactating
women; and study ID-078-118 is a single-
center, randomized, double-blind, single-dose,
3-way crossover study to compare the effects of
daridorexant and placebo on postural stability,
the auditory awakening threshold, and cognitive
function in the middle of the night following
evening administration to healthy adult and
elderly subjects."

Ronapreve - Casirivimab / Imdevimab -
EMEA/H/C/005814/II/0014
Roche Registration GmbH, Rapporteur: Jan
Mueller-Berghaus, "Submission of the final
report from study R10933-10987-COV-2118
(COV-2118) - A Phase 2 Randomized, Open-
Label, Parallel Group Study to Assess the
Immunogenicity, Safety, and Tolerability of
Moderna mRNA-1273 Vaccine Administered with
Casirivimab+Imdevimab in Healthy Adult
Volunteers."

SARCLISA - Isatuximab -
EMEA/H/C/004977/II/0025
Sanofi Winthrop Industrie, Rapporteur: Peter Mol, "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to amend an existing warning on second primary malignancies and to update efficacy and safety information based on Overall Survival analysis from study EFC15246 (IKEMA - Randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines). In addition, the MAH took this opportunity to introduce editorial changes to the PI."

**Spinraza - Nusinersen - EMEA/H/C/004312/II/0032, Orphan**
Biogen Netherlands B.V., Rapporteur: Bruno Sepodes, "Update of section 4.8 of the SmPC in order to add 'Arachnoiditis' to the list of adverse drug reactions (ADRs) with frequency not known, based on postmarketing review. The Package Leaflet is updated accordingly."

**Sunlenca - Lenacapavir - EMEA/H/C/005638/II/0013**
Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, "Update of section 5.3 of the SmPC in order to update non-clinical information based on final results from study TX-200-2046 entitled, "104 Week Subcutaneous Injection Carcinogenicity and Toxicokinetic Study of GS-6207 Administered Every 13 Weeks in Wistar-Han Rats". In addition, the MAH took the opportunity introduce minor editorial changes to the PI."

**TAGRISSO - Osimertinib - EMEA/H/C/004124/II/0054**
AstraZeneca AB, Rapporteur: Carolina Prieto Fernandez, "Update of section 4.8 of the SmPC to add 'Skin Hyperpigmentation' to the list of adverse drug reactions (ADRs) with frequency 'uncommon' based on literature. The package leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

**TEPMETKO - Tepotinib - EMEA/H/C/005524/II/0011**
Merck Europe B.V., Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC in order to add alternative methods of administration dispersed in water, as oral drinking suspension or via feeding tubes based on the available physicochemical and clinical pharmacology data. The Package Leaflet is updated accordingly."

**Ultomiris - Ravulizumab -**
**EMEA/H/C/004954/II/0041**
Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update the frequency of adverse reactions and to update pharmacokinetic, efficacy and safety information on PNH based on final results from studies ALXN1210-PNH-304, ALXN1210-PNH-301 (listed as a category 3 study in the RMP), ALXN1210-PNH-201 and ALXN1210-PNH-103. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to align the warning in Annex II and the PI where male patients should not father a child or donate sperm up to eight months after treatment and to introduce editorial changes."

**Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) -**
**EMEA/H/C/003982/II/0137**
MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to add information on rates of predicted protection against pertussis, based on a validated model that correlates anti-pertussis antibody levels with protection against pertussis; this is a modelling study that applied the validated Storsaeter-Kohberger model to the pertussis pre-vaccination and post-vaccination ELISA outputs from Phase 3 studies V419-007 and V419-008."

**Venclyxto - Venetoclax -**
**EMEA/H/C/004106/II/0047**
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Submission of the final report from study GO28667 (MURANO) listed as a category 3 study in the RMP. This is a Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia to Evaluate the

**Vocabria - Cabotegravir**

**EMEA/H/C/004976/II/0019**

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Update of section 4.2 of the SmPC in order to update administration instructions to mitigate product leakage related to the correct use of the vial adapter, based on Human Factor studies. The Package Leaflet (Instructions for Use) is updated accordingly."

**Volibris - Ambrisentan**

**EMEA/H/C/000839/II/0067**

GlaxoSmithKline (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, "To update sections 4.8 and 5.1 of the SmPC following the assessment of Art 46 procedure (EMEA/H/C/000839) based on final results from study AMB114588; this is an open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired. In addition, the MAH took the opportunity to implement minor editorial changes to Annex II and to the Package Leaflet."

**Wegovy - Semaglutide**

**EMEA/H/C/005422/II/0018**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt, "Update of section 4.8 of the SmPC in order to add ‘Dysgeusia’ to the list of adverse drug reactions (ADRs) with frequency ‘Common’ based on results from clinical studies, post-marketing data and literature. The Package Leaflet is updated accordingly."

**Xevudy - Sotrovimab**

**EMEA/H/C/005676/II/0024**

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.1 of the SmPC in order to include virology information based on data from various pharmacology studies on the in vitro activity of sotrovimab in a pseudotyped virus assay against the SARS-CoV-2 Omicron XBB.1.16 and XBB.2.3 spike variants (PC-23-0137), the XBB.1.16.1 and XBB.1.5.10 spike variants."

---

**EMEA/CHMP/506429/2023**  Page 70/86
variants (PC-23-0151), and Omicron spike variants encoding epitope substitutions (PC-22-0108), as well as data on the in vitro activity of sotrovimab in an authentic virus assay against the SARS-CoV-2 XBB.1.16 variant (PC-23-0146), and the SARS-CoV-2 BA.2.75, BA.4.6 and BQ.1.1 variants (PC-23-0139).”

WS2583
Stayveer-
EMEA/H/C/002644/WS2583/0040
Tracleer-
EMEA/H/C/000401/WS2583/0105
Janssen-Cilag International N.V., Lead Rapporteur: Alexandre Moreau, “Update of section 4.4 of the SmPC to update the wording concerning breast feeding based on literature and post-marketing data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

WS2597
OPDIVO-
EMEA/H/C/003985/WS2597/0138
Yervoy-EMEA/H/C/002213/WS2597/0107
Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Carolina Prieto Fernandez, "Update of section 4.8 of the SmPC in order to add 'myelitis' to the list of adverse drug reactions (ADRs) based on post-marketing data and literature; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

WS2603
Eucreas-
EMEA/H/C/000807/WS2603/0105
Galvus-EMEA/H/C/000771/WS2603/0082
Icandra-
EMEA/H/C/001050/WS2603/0110
Jaara-EMEA/H/C/001048/WS2603/0085
Xiliarx-EMEA/H/C/001051/WS2603/0083
Zomarist-
EMEA/H/C/001049/WS2603/0107
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add 'Cholecystitis' to the list of adverse drug reactions (ADRs) with frequency 'Not known'. The Package Leaflet is updated
B.6.10. CHMP-PRAC assessed procedures

Beyfortus - Nirsevimab -
EMEA/H/C/005304/II/0018/G
Sanofi Winthrop Industrie, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Kimmo Jaakkola, “Grouped application comprising two type II variations as follows:
C.I.13: Submission of the final report from study D5290C00004 (MELODY) listed as a category 3 study in the RMP. This is a phase III study, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of MEDI8897, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants.
C.I.13: Submission of the final report from study D5290C00005 (MEDLEY) listed as a category 3 study in the RMP. This is a phase II/III study, randomized, double-blind, placebo-controlled study to evaluate the safety of Beyfortus (nirsevimab) in high-risk children. The RMP version 2.3 has also been submitted.”

BIMERVAX - SARS-CoV-2 virus, variants
B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer -
EMEA/H/C/006058/II/0010
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Zane Neikena, "Submission of the final report from study HIPRA-HH-5, "A phase III, open label, single arm, multi-center, trial to assess the safety and immunogenicity of a booster vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-COV-2, in adults vaccinated against COVID-19". The RMP version 1.3 has also been submitted.”

Enhertu - Trastuzumab deruxtecan -
EMEA/H/C/005124/II/0040

**MenQuadfi - Meningococcal Group A, C, W and Y conjugate vaccine -**

EMEA/H/C/005084/II/0027

Sanofi Pasteur, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, “Submission of the final report from study MET52, listed as a category 3 study in the RMP. This was a Phase III, open-label, randomized, parallel-group, active-controlled, multi-center study to evaluate the immunogenicity and describe the safety of MenACYW conjugate vaccine when administered concomitantly with a Meningococcal Group B vaccine and other routine pediatric vaccines as part of the National Immunization Schedule in healthy infants and toddlers in the United Kingdom. The RMP version 1.3 has also been submitted.”

**Spravato - Esketamine -**

EMEA/H/C/004535/II/0020

Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Kirsti Villikka, “Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on severe hepatic impairment and to include the long-term safety information based on final results from study 54135419TRD3008 (An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression), listed as a category 3 study in the RMP; This was a multicenter, open-label, long-term extension safety study to evaluate safety, tolerability, and efficacy of esketamine in participants with TRD. The RMP version 5.1 has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes to the PI.”

**Tecentriq - Atezolizumab -**

EMEA/H/C/004143/II/0083/G

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ana Sofia Diniz
Martins, "A grouped application comprising of 2 Type II variations, as follows:

C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study IMvigor210 (GO29293) listed as a PAES in the Annex II; this is a Phase II, multicenter, single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer. The Annex II is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the latest QRD template.

C.I.13: Submission of the final report from study SAUL (MO29983) listed as a category 3 study in the RMP. This is an open-label, single arm, multicenter, safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract. The RMP version 30.0 has also been submitted."

**Vabysmo - Faricimab -**
**EMEA/H/C/005642/II/0009**
Roche Registration GmbH, Rapporteur: Jayne Crowe, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of section 4.8 of the SmPC in order to add 'Retinal Vasculitis' and 'Retinal Occlusive Vasculitis' to the list of adverse drug reactions (ADRs) with frequency not known, based on a drug safety report and post-marketing data; the Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to add study CR45271 as a category 3 study in the RMP, to introduce minor changes and corrections to the PI and to update the list of local representatives in the Package Leaflet."

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -**
**EMEA/H/C/005675/II/0096**
AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.8 and 5.1 of the SmPC based on final results from study D7220C00001; this is a phase 2/3 partially double-blinded, randomised, multinational, active-controlled study in both previously vaccinated and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of SARS-
CoV-2. The RMP version 8 s1 has also been submitted.”

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0097**
AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Submission of the final report from study D8110C00001 listed as a category 3 study in the RMP (SOB/020). This is a phase III, randomised, placebo-controlled study of AZD1222 (Vaxzevria) conducted in the US, Peru and Chile. The purpose of the final CSR addendum is to provide long-term safety data through to study completion and include the second year of follow-up post-first dose and final day 730 visit. The RMP version 8 s2 has also been submitted.”

**Vyvgart - Efgartigimod alfa - EMEA/H/C/005849/II/0014, Orphan**
Argenx, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald, "Update of section 4.4 of the SmPC in order to amend an existing warning on infusion reactions and hypersensitivity reactions, and update of section 5.1 of the SmPC to update the mechanism of action of efgartigimod in relation to albumin; based on final results from study ARGX-113-1705 listed a category 3 study in the RMP. This is a long-term, single-arm, open-label, multicenter, phase 3 follow-on study of ARGX-113-1704 to evaluate the safety and tolerability of ARGX-113 in patients with myasthenia gravis having generalised muscle weakness. The RMP version 2.2 has also been submitted.”

**Xevudy - Sotrovimab - EMEA/H/C/005676/II/0026**
Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Liana Martirosyan, "To update sections 4.2, 4.8 and 5.2 of the SmPC in order to update information on paediatric population based on final results from study COMET-PACE (215226), a category 3 study in the RMP; this is an open-label, non-comparator, multicentre study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in paediatric participants with mild to moderate COVID-19 at high risk of
disease progression. The updated RMP version 1.1 has also been submitted.”

**Zeposia - Ozanimod -**

*EMEA/H/C/004835/II/0023*

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, “Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on the final results from study RPC01-3001, listed as a category 3 study in the RMP. This is a multi-site, open label extension trial of RPC1063 in relapsing multiple sclerosis. The study’s main objectives were to characterise the long-term safety and tolerability, and the long-term efficacy of ozanimod in patients with relapsing multiple sclerosis. The RMP version 7.0 has also been submitted.”

**B.6.11. PRAC assessed procedures**

**PRAC Led**

**BLINCYTO - Blinatumomab -**

*EMEA/H/C/003731/II/0054, Orphan*

Amgen Europe B.V., PRAC Rapporteur: Jana Lukacisinova, PRAC-CHMP liaison: Petr Vrbata, “To update sections 4.2, 4.4 and 4.8 of the SmPC to include Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS); and to update section D of Annex II to remove educational materials for physicians, pharmacists and nurses and to include ICANS within neurologic events in educational material for patient/caregivers and patient alert card following the outcome of PSUR procedure EMEA/H/C/PSUSA/00010460/202212. The Package Leaflet is updated accordingly. The RMP version 17.0 has also been submitted.”

**PRAC Led**

**Entyvio - Vedolizumab -**

*EMEA/H/C/002782/II/0081*

Takeda Pharma A/S, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, “Update of section 4.6 of the SmPC in order to update information on pregnancy based on final results from study Vedolizumab-5001 (OTIS Entyvio Pregnancy Exposure Registry); this is a non-interventional study to monitor planned and unplanned
pregnancies in female patients with ulcerative colitis or Crohn’s disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes and corrections to the PI and bring it in line with the latest QRD template.”

PRAC Led  
**Evrysdi - Risdiplam -**  
EMEA/H/C/005145/II/0020  
Roche Registration GmbH, PRAC Rapporteur: Jan Neuhauser, PRAC-CHMP liaison: Daniela Philadelphy, “Submission of an updated RMP version 2.0 in order to remove the important potential risk of retinal toxicity with risdiplam due to the absence of evidence of retinal toxicity based on thorough ophthalmological monitoring in clinical studies to date.”

PRAC Led  
**Instanyl - Fentanyl -**  
EMEA/H/C/000959/II/0082  
Takeda Pharma A/S, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study Instanyl-5002 listed as a category 3 study in the RMP. This is a non-interventional PASS study with title “Assessment of the Effectiveness of Updated Educational Materials on Prescribers' Knowledge and Behavior with Respect to Risks Associated with INSTANYL Off-Label Use”. The RMP version 20.0 has also been submitted.”

PRAC Led  
**MabThera - Rituximab -**  
EMEA/H/C/000165/II/0201/G  
Roche Registration GmbH, PRAC Rapporteur: Karin Erneholm, PRAC-CHMP liaison: Aaron Sosa Mejia, “A grouped application comprising of: Type II (C.I.3.b): Update of sections 4.1, 4.2, 4.3, 4.8, 5.1, 6.2, 6.4 and 6.5 of the SmPC in order to introduce several structural and editorial changes to align with the current SmPC guideline and to remove the educational materials for HCPs and patients, following the request by the PRAC in the AR for the PSUSA procedure EMA/PRAC/257005/2023. The Annex II, Labelling and Package Leaflet are updated accordingly. The RMP version 25.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes
to the PI and to update the list of local representatives in the Package Leaflet. 
Type I (A.6): To change the ATC Code of rituximab from L01XC02 to L01FA01.”

PRAC Led

**Mosquirix - Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)** -  
**EMEA/H/W/002300/II/0077**
GlaxoSmithkline Biologicals SA, PRAC
Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, “Submission of the final report from study EPI-MALALARIA-002 VS AME (115055). This is a non-interventional study, designed to estimate the incidence of diseases specified as adverse events of special interest, of other adverse events leading to hospitalisation or death, and of meningitis in infants and young children in sub-Saharan Africa.”

PRAC Led

**Mysimba - Naltrexone hydrochloride / Bupropion hydrochloride** -  
**EMEA/H/C/003687/II/0066**
Orexigen Therapeutics Ireland Limited, PRAC
Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “Submission of final report from study NB-453, listed as a category 3 study in the RMP. This is a noninterventional qualitative research using online focus groups to assess understanding, attitude and behaviour for usage of the Mysimba Physician Prescribing Checklist (PPC) among physicians in the European Union (EU), following a previous cross-sectional survey that aimed at evaluating the effectiveness of the same PPC (study NB-452). The RMP version 12.10 has also been submitted.”

PRAC Led

**Prolia - Denosumab** -  
**EMEA/H/C/001120/II/0100**
Amgen Europe B.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, “Submission of the final report from the postmarketing observational study 20090522, listed as a category 3 study in the RMP. This is a denosumab global safety assessment among women with postmenopausal osteoporosis (PMO), men with osteoporosis, and men and women who receive Prolia with glucocorticoid
exposure in multiple observational databases."

PRAC Led

**RAYVOW - Lasmiditan -**

**EMEA/H/C/005332/II/0005**

Eli Lilly Nederland B.V., PRAC Rapporteur: Anna Mareková, PRAC-CHMP liaison: Frantisek Drafi, 
"Submission of an updated RMP version 1.1 in order to include a descriptive interim analysis in the study design of study H8H-MC-B006, listed as a category 3 study in the RMP. This is a non-interventional study titled ‘Lasmiditan Use and Motor Vehicle Accidents in Real-World Settings in the US’."  

PRAC Led

**SARCLISA - Isatuximab -**

**EMEA/H/C/004977/II/0024**

Sanofi Winthrop Industrie, PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Carolina Prieto Fernandez, "Submission of the final report from study SARSAC09715, listed as a category 3 study in the RMP. This is a non-interventional survey to evaluate the effectiveness of the isatuximab educational materials to minimise the risk of interference for blood typing (minor antigen) (positive indirect Coombs test). The RMP version 1.3 has also been submitted."

PRAC Led

**SCENESSE - Afamelanotide -**

**EMEA/H/C/002548/II/0049, Orphan**

Clinuvel Europe Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of the final report from study CUV-RCR-001 (Scenesse (Afamelanotide 16mg) Retrospective Chart Review) listed as an obligation in the Annex II of the Product Information. This is a retrospective study comparing long term safety data and outcome endpoints in patients receiving and not receiving Scenesse, or having discontinued Scenesse use. The Annex II and the RMP (version 9.6) are updated accordingly."

PRAC Led

**Spravato - Esketamine -**

**EMEA/H/C/004535/II/0021**

version 5.2 in order to remove "use during pregnancy" as missing information from the list of safety concerns, with the consequential removal of the associated category 3 additional pharmacovigilance activity, the National Pregnancy Registry for Antidepressants ("Massachusetts General Hospital (MGH) pregnancy registry).”

PRAC Led
**Stelara - Ustekinumab -**
**EMEA/H/C/000958/II/0104**
Janssen-Cilag International N.V., PRAC
Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, “Submission of the final report from study RRA-20745 listed as a category 3 study in the RMP. This is an observational post-authorisation safety study (PASS) to describe the safety of ustekinumab and other Crohn’s disease treatments in a cohort of patients with Crohn’s disease. The RMP version 27.2 has also been submitted.”

PRAC Led
**TachoSil - Human thrombin / Human fibrinogen - EMEA/H/C/000505/II/0124**
Corza Medical GmbH, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Submission of an updated RMP version 9.1 in order to reflect the extension of indication to include the paediatric population and to update the details of the planned non-interventional post-authorisation safety study: PASS-TachoSil Evaluation (PasTel).”

PRAC Led
**Zessly - Infliximab -**
**EMEA/H/C/004647/II/0033**
Sandoz GmbH, PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, “Submission of an updated RMP version 4.0 in order to remove the UKIBD (UK) registry from the additional pharmacovigilance activities.”

PRAC Led
**WS2577**
**Kinzalmono-**
**EMEA/H/C/000211/WS2577/0120**
**Micardis-**
**EMEA/H/C/000209/WS2577/0129**
**Pritor-**
**EMEA/H/C/000210/WS2577/0133**
Boehringer Ingelheim International GmbH, Lead Rapporteur: Paolo Gasparini, Lead PRAC
Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Paolo Gasparini, "Submission of an updated RMP version 6.1 in order to implement an overall update regarding safety concerns based on literature and post-marketing data; and to adapt the RMP to the current RMP format (Rev 2.0.1), in line with GVP Module V, Revision 2."

PRAC Led
**WS2587**
TECFIDERA-
EMEA/H/C/002601/WS2587/0085
Vumerity-
EMEA/H/C/005437/WS2587/0015
Biogen Netherlands B.V., Lead PRAC
Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study 109MS401, a multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera (Dimethyl Fumarate) when used in routine medical practice in the treatment of Multiple Sclerosis (ESTEEM), listed as a category 3 study in the RMP (MEA007.6). The RMPs version 16.1 for Tecfidera and version 2.1 for Vumerity, have also been submitted."

PRAC Led
**WS2591/G**
Hefiya-
EMEA/H/C/004865/WS2591/0050/G
Hyrimoz-
EMEA/H/C/004320/WS2591/0049/G
Sandoz GmbH, Lead Rapporteur: Christian Gartner, Lead PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "C.I.13: Submission of the final report from study RABBIT. This is a German registry for the long-term observation of therapy with biologics in adult patients with rheumatoid arthritis. C.I.13: Submission of the final report from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). This is a registry to investigate the long-term safety outcomes of psoriasis patients treated with biologic therapy. C.I.13: Submission of the final report from the Inflammatory Bowel Disease Registry (UK-IBD). This registry was used to identify adverse
reactions to Hyrimoz in a cohort of inflammatory bowel disease patients managed in a real-world setting.”

PRAC Led
WS2604
Riarify-EMEA/H/C/004836/WS2604/0029
Trydonis-
EMEA/H/C/004702/WS2604/0034
Chiesi Farmaceutici S.p.A., Informed Consent of Trimbow, Lead PRAC Rapporteur: Jan Neuhauser, PRAC-CHMP liaison: Christian Gartner, "C.I.11.z - To provide a new version of the RMP for Riarify and Trydonis in order to:
- update the post-authorisation exposure data
- replace the protocol of the PASS study for study CLI-05993BA1-05 in Annex 3, following its approval via procedure EMEA/H/X/004257/MEA/002.3."

PRAC Led
WS2611
Kinzalkomb-
EMEA/H/C/000415/WS2611/0123
MicardisPlus-
EMEA/H/C/000413/WS2611/0130
PritorPlus-
EMEA/H/C/000414/WS2611/0133
Boehringer Ingelheim International GmbH, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Paolo Gasparini, "Submission of an updated RMP version 9.1 for MicardisPlus, PritorPlus and Kinzalkomb in order to remove all important identified and potential risks from the list of safety concerns and to adapt the RMP to the current RMP format (Rev 2.0.1), in line with GVP Module V, Revision 2."

PRAC Led
WS2615
Abseamed-
EMEA/H/C/000727/WS2615/0108
Binocrit-
EMEA/H/C/000725/WS2615/0108
Epoetin alfa Hexal-
EMEA/H/C/000726/WS2615/0108
Sandoz GmbH, Lead PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from Non-Interventional Post authorisation Safety Study, NI-PASS HX575-507 listed as a category 3 study in the RMP. The non-interventional study
(NIS PASS) study HX575-507 was conducted to address a post-approval requirement (MEA 13.5) to evaluate the safety profile of HX575 administered s.c. in patients with CKD-induced anemia under real-life conditions, in order to increase confidence on the safe use of s.c. HX575. The RMP version 19.0 has also been submitted.”

**B.6.12. CHMP-CAT assessed procedures**

**Alofisel - Darvadstrocel -**
EMEA/H/C/004258/II/0047/G, Orphan, ATMP
Takeda Pharma A/S, Rapporteur: Maria Luttgen,
CHMP Coordinator: Kristina Dunder

**Tecartus-**
EMEA/H/C/005102/WS2607/0039

**Yescarta-**
EMEA/H/C/004480/WS2607/0067
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

**B.6.13. CHMP-PRAC-CAT assessed procedures**

**B.6.14. PRAC assessed ATMP procedures**

**B.6.15. Unclassified procedures and worksharing procedures of type I variations**

**WS2475/G**
Revatio-
EMEA/H/C/000638/WS2475/0109/G
Viagra-
EMEA/H/C/000202/WS2475/0121/G
Upjohn EESV, Lead Rapporteur: Patrick Vrijlandt

**WS2518/G**
Combivir-
EMEA/H/C/000190/WS2518/0110/G
Epivir-
EMEA/H/C/000107/WS2518/0127/G
Kivexa-
EMEA/H/C/000581/WS2518/0097/G
Trizivir-
EMEA/H/C/000338/WS2518/0132/G
ViiV Healthcare B.V., Lead Rapporteur: Jean-
<table>
<thead>
<tr>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS2584</strong></td>
</tr>
<tr>
<td>HyQvia-EMEA/H/C/002491/WS2584/0094</td>
</tr>
<tr>
<td>Kiovig-EMEA/H/C/000628/WS2584/0125</td>
</tr>
<tr>
<td>Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS2601</strong></td>
</tr>
<tr>
<td>Nuwiq-EMEA/H/C/002813/WS2601/0057</td>
</tr>
<tr>
<td>Vihuma-EMEA/H/C/004459/WS2601/0039</td>
</tr>
<tr>
<td>Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS2606/G</strong></td>
</tr>
<tr>
<td>M-M-RvaxPro-EMEA/H/C/000604/WS2606/0122/G</td>
</tr>
<tr>
<td>ProQuad-EMEA/H/C/000622/WS2606/0164/G</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS2617</strong></td>
</tr>
<tr>
<td>Blitzima-EMEA/H/C/004723/WS2617/0071</td>
</tr>
<tr>
<td>Truxima-EMEA/H/C/004112/WS2617/0074</td>
</tr>
<tr>
<td>Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS2624</strong></td>
</tr>
<tr>
<td>Abseamed-EMEA/H/C/000727/WS2624/0109</td>
</tr>
<tr>
<td>Binocrit-EMEA/H/C/000725/WS2624/0109</td>
</tr>
<tr>
<td>Epoetin alfa Hexal-EMEA/H/C/000726/WS2624/0109</td>
</tr>
<tr>
<td>Sandoz GmbH, Lead Rapporteur: Alexandre Moreau</td>
</tr>
</tbody>
</table>
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)


B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers

E.2. Time Tables – starting & ongoing procedures: For information

| PMF timetables starting and ongoing procedures | Tabled in MMD and sent by post mail (folder E). |

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.
G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

H. ANNEX H - Product Shared Mailboxes – e-mail address